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 Regulation of Sickle Cell Disease Specific Erythrocyte Adhesion 
Jing Zhang, PhD 
University of Connecticut, 2019 
Human red blood cells (RBCs) provide essential gaseous exchanges to all body’s tissues and 
organs through the circulatory system. RBCs lack of nucleus and organelles provides as much 
room as possible for the oxygen-carrying protein hemoglobin. Hemoglobin composes ~98% of 
the soluble proteins in mature RBCs. RBCs have a biconcave shape corresponding to a large 
cellular surface area-to-volume ratio allowing for efficient gas exchange and increased cell 
deformability ensuring passage through the narrowest capillaries without rupturing and vessel 
obstruction. In sickle cell disease (SCD), a single point mutation occurs in the beta-globin gene, 
resulting in the production of abnormal hemoglobin (HbS) which, in deoxygenated conditions, 
polymerizes to form stiff filaments deforming SCD RBCs (SS-RBCs) to a wide variety of sickle 
shapes. In addition to the irregular shape, SS-RBCs are stiffer, more viscous, and show higher 
adhesion than normal (wild-type) WT-RBCs to other RBCs, platelets, leukocytes, and to the 
endothelium. Consequently, abnormal SS-RBC adhesion leads to delayed microvascular 
passage of deoxygenated RBCs inducing sickling and entrapment of RBCs, a key trigger of vaso-
occlusive episodes (VOEs) which is the pathophysiologic hallmark of SCD. 
We employed a powerful technique called single-molecule force spectroscopy to investigate the 
mechanism of RBC adhesion and signaling, and to guide advances in SCD pharmacotherapy. 
Specifically, we studied the effect of the cyclic adenosine monophosphate-protein kinase A 
(cAMP-PKA) dependent signaling pathway on the activation of intercellular adhesion molecule-4 
(ICAM-4) receptors, which express on the RBC surface and bind with high-affinity to endothelial 
αvβ3 integrin, in turn, inducing endothelial injury and inflammation likely contributing to VOEs in 
Jing Zhang – University of Connecticut, 2019 
SCD. We demonstrated that the activation of ICAM-4 receptors is regulated via the cAMP-PKA 
pathway and importantly we determined for the first time that this activation is mediated by A-
kinase anchoring proteins (AKAPs). We also investigated the possibility of receptor cross-talk 
between the β-adrenergic receptor (β-AR) and the angiotensin II type 1 receptor (AT1R), which 
resulted in a trans-inhibitory effect of valsartan on the ICAM-4 activation. These findings may lead 
to novel pharmacological approaches for the prevention and treatment of VOEs. 
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Chapter 1. Introduction 
1.1. Human erythrocytes 
Red blood cells (RBCs), also known as red cells, erythroid cells or erythrocytes are the most 
common type of blood cell and provide essential gaseous (O2, CO2) exchanges to tissues and 
organs ensuring them to sustain their normal functions (1-4). RBCs were also considered for a 
long time as a scavenger of endothelial cell-derived nitric oxide (NO), modulating the balance 
between NO formation and inhibition (5), participating in systemic NO metabolism (6, 7). RBCs 
were first observed and described by a Dutch biologist and microscopist, Jan Swammerdam in 
1668. Later in 1675 another Dutch microscopist, Antonie van Leeuwenhoek, first published a 
remarkable description of the unique features of human RBCs, which stated in a healthy body 
RBCs should be soft and flexible, that they may be capable of passing through the capillaries, by 
easily changing their round shapes into ovals, and also reassuming their former roundness when 
they come into larger vessels (8-10). All blood cells, including erythrocytes, leukocytes and 
platelets, arise from the same bone marrow stem cells that acquire their unique characteristics 
after undergoing a process of specialization (11-15). In humans, RBCs develop in the bone 
marrow from haematopoietic stem and progenitor cells (HSPCs) via a complex maturation 
cascade known as erythropoiesis and live for about 120 days (16-20). The formation of RBCs is 
a dramatic process due to purging most of the organelles, such as nucleus, mitochondria, 
ribosomes and more, in order to make as much room as possible for the oxygen-carrying protein 
hemoglobin. Towards the end of erythropoiesis, immature red blood cells also known as 
reticulocytes (multi-lobular and spherical) experience dynamic re-arrangements to yield highly 
deformable biconcave erythrocytes (normocytes), which nourish the body with oxygen through 
the circulatory system (16, 21-23). In the rapid transition of reticulocyte to RBC, UBE20, an E2-
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E3 hybrid enzyme, serve as the main drive. UBE20 recognizes and ubiquitinates myriad proteins 
that are fated for elimination. The target proteins are then degraded by the proteasome and 
ubiquitin is recycled  (24). Eventually, RBCs take the form of flexible biconcave disks that lack a 
cell nucleus and organelles and they cannot synthesize protein. The molecular mechanisms 
underpinning these remarkable morphological and bio-mechanical transformations were deeply 
studied through quantitative profiling of protein composition and imaging (16) and quantitative 
mass spectrometry techniques (16, 24). In the mature RBCs, hemoglobin composes ~98% of the 
soluble proteins (24). RBCs take up oxygen in the lungs through binding to hemoglobin and 
release it while flowing through the body's circulatory system. The blood's red color is due to the 
color of oxygen-rich hemoglobin (25-27). 
The biconcave shape of the human RBCs is fundamental for their physiological function as it 
increases overall cell deformability and creates a high cellular surface area-to-volume ratio 
allowing for efficient gas exchange (1, 28-31). It can be critically affected by genetic or acquired 
pathological conditions (1, 28). To deliver oxygen to the tissues, RBCs must be able to 
dynamically adapt to and compensate for the constantly changing flow conditions along the 
vascular tree and particularly in the narrowest capillaries to deform significantly without rupturing 
and obstructing the vessels (32).  
Equivalently important is that RBCs express more than 50 transmembrane proteins of various 
abundance ranging from a few hundred to a million copies. These membrane proteins exhibit 
diverse functional heterogeneity, serving as transport proteins, as signaling receptors, and as 
adhesion proteins involved in the interactions of RBCs with other blood cells and endothelial cells 
(33-38). Adhesion molecules mediate intercellular adhesion mechanisms and interactions with 
proteins of the extracellular matrix (39-42). Adhesion molecules carrying blood group antigens 
(like CD44, Lu, LW, CD47, and CD147) are involved in the pathophysiology of malaria, sickle cell 
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disease (SCD) and diabetes, as well as in thrombosis, mainly through an abnormal adhesion to 
the vascular endothelium (43-49). Meanwhile, adhesion molecules on RBCs might also interact 
with the developing thrombus, for instance through interaction with cells expressing integrins, 
such as activated leukocytes, monocytes and platelets (44, 50). 
 
1.2. Sickle cell disease and sickle cell trait 
Sickle cell disease (SCD) was first described by the Chicago physician, Dr. James B Herrick in 
1910 (51-54). In the blood examination of a young African descent patient, there were a large 
number of thin, elongated, sickle-shaped and crescent-shaped red corpuscles. These peculiar 
elongated forms of the red corpuscles were never saw and no conclusions could be drawn from 
the case at the time (52). It was almost 4 decades later that Linus Pauling and his 
colleagues revealed that SCD was caused by a genetic disorder (55). SCD is a group of blood 
disorders that result from a recessively inherited point mutation occurring in the β-globin gene and 
lead to altered membrane and cell functions (56-58). The point mutation replaces A with T at 
codon 6 of beta hemoglobin chain (59). This causes the switch of protein production from glutamic 
acid (charged) to valine amino acid (hydrophobic) at the beta 6 site and gives rise to abnormal 
(sickle) hemoglobin (HbS). The valine-type hemoglobin polymerizes to form stiff filaments when 
exposed to low oxygen conditions (60-62), causing a distortion in the shape of the RBCs from 
biconcave to sickled. Because of their distorted shape, RBCs carrying the defective hemoglobin 
HbS are called sickle RBCs (SS-RBCs). In addition to their irregular shape, compared with normal 
(wild-type, WT) RBCs, SS-RBCs are stiffer and more viscous, and show higher adhesion to other 
RBCs, platelets, leukocytes, and the endothelium (43, 44, 61, 63-67). In SCD, an abnormally high 
expression of α4β1 (VLA-4, fibronectin receptor), CD36 (thrombospondin receptor) and adhesion 
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molecules like BCAM(Lu, CD239) and ICAM-4 (LW, CD242) on the RBC surface contributes 
largely to their adhesion to the activated endothelium surface, thus leading to a decreased blood 
flow and delayed microvascular passage of deoxygenated RBCs, inducing sickling and 
entrapment of RBCs, sequentially, to occurrence of serious vaso-occlusive problems which are 
among the major clinical complications (painful crisis, acute chest syndrome, infections, strokes) 
in this disease (68-74).  
As the key adhesion molecule mediating the adhesion between RBCs and endothelium, LW 
antigens reside on a 42-kDa red cell membrane glycoprotein named CD242, encoded by a gene 
located on chromosome 19 (75, 76). The LW glycoprotein was renamed ICAM-4 based on strong 
sequence similarities with the intercellular adhesion molecule (ICAM) family, a group of molecules 
that play a crucial role in cell-cell interactions (77-79). In SCD, abnormal adhesion of RBCs to 
endothelial cells is primarily mediated by the intercellular adhesion molecule -4 (ICAM-4) which 
expresses on the RBC membrane and binds to the endothelial αvβ3 integrin (80-82). This is a 
key factor in triggering vaso-occlusive episodes (VOEs), the hallmark of SCD. Better 
understanding of the mechanisms that control RBC adhesion to the endothelial cells may lead to 
novel approaches for both prevention and treatment of VOEs in SCD. One important mechanism 
of ICAM-4 activation is via the cyclic adenosine monophosphate-protein kinase A (cAMP-PKA) 
dependent signaling pathway (83-86). 
In homozygous SCD, irreversibly sickled red cells are seen in routine peripheral blood smears 
(87-89). From its onset, the disease runs an unremitting course punctuated by sudden crises. 
Homozygous SCD usually is asymptomatic until 6 months of age when the shift from HbF to HbS 
is complete. The anemia is moderate to severe; most patients have hematocrits of 18% to 30% 
(normal range, 38% to 48%) (90). In addition to these crises, patients with SCD are prone to 
infections. Both children and adults with SCD are functionally asplenic, making them susceptible 
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to infections caused by encapsulated bacteria, such as pneumococci. There are also common 
complications, such as pulmonary hypertension, acute chest syndrome, stroke, unhealing leg 
ulcers, and eye damage (91).  
The clinical course of SCD is highly variable (92). As a result of improvements in supportive care, 
an increasing number of patients are surviving into adulthood. Approximately 50% of patients now 
survive beyond the fifth decade (93). Current Treatment involves a number of measures. A 
mainstay of therapy is hydroxyurea, so far the only FDA-approved drug to treat SCD. Hydroxyurea 
reduces pain crises and lessens the anemia through several effects, including 1) an increase in 
levels of HbF; 2) an anti-inflammatory effect because of the inhibition of white cell production; 3) 
an increase in RBC size, which lowers the intracellular hemoglobin concentration; and 4) its 
metabolism to NO, a potent vasodilator and inhibitor of platelet aggregation (94-100). However, 
only two-thirds of patients respond favorably to the drug. There are pain medications for various 
pain levels. Antibiotics such as penicillin and routine vaccinations are used to prevent infections 
in babies and young children. Blood transfusions are widely used to treat worsening anemia and 
sickle cell complications. Encouraging results also have been obtained with allogeneic bone 
marrow transplantation, which is potentially curative. But due to its significant risks, transplants 
are not appropriate for every patient (101-104). Lately, anti-adhesive therapies have drawn much 
attention due to the possibility of attenuating vaso-occlusion. New medicines have shown positive 
results on pre-clinical data and clinical trials (105-114). 
Sickle cell trait (SCT) is a heterozygous state characterized by the presence of both normal 
hemoglobin (HbA) and HbS (115-117). Patient with sickle cell trait receives HbS from one parent 
and HbA from the other parent. While patients with SCD suffer increased mortality and often 
widespread chronic organ damage, individuals with SCT are generally asymptomatic and live a 
normal lifespan (118). However, under extreme conditions, such as hypoxia, acidosis, and 
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dehydration, individuals with SCT can develop a syndrome resembling SCD with vaso-occlusive 
sequelae (119-122). 
As of 2015, about 4.4 million people have sickle cell disease worldwide, while 404 million have 
sickle cell trait (123, 124). Painful vaso-occlusive crises are often treated symptomatically with 
pain medications rather than treat the underlying cause; pain management requires opioid 
administration at regular intervals until the crisis has settled. This has contributed significantly to 
the low quality of life endured by those that live with this disease (125). It is estimated in the U.S. 
alone that there are ~200,000 emergency department presentations annually for VOE pain (126). 
These acute care costs approximate $1 billion a year (127). Clearly, there are both patient-
centered and societal reasons requiring further research in this area. 
One of the limitations of current research is that while it is known that VOEs are at least in part 
due to interactions between RBCs and the endothelium via receptor-ligand including BCAM/Lu-
laminin (128) and ICAM-4-αvβ3 (129), the quantitative understanding of this biomechanical 
process is limited. It is not known how the expression of functionally active adhesion receptors 
varies (1) between individuals with SCD and (2) during the onset of VOE. 
 
1.3. AFM biomedical techniques and applications 
Atomic Force Microscopy (AFM) is a type of high-resolution scanning probe microscopy that 
allows for imaging, manipulation and force measurement (130-135). It is a widely used and 
powerful technique for investigating materials at a nanoscale range. AFM was invented in 1986 
by Binnig, Quate, and Gerber as a way of overcoming the drawbacks of scanning tunneling 
microscopy (STM) (136). It is used in a variety of different scientific areas, including solid-state 
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physics, semiconductor science, molecular engineering, polymer and surface chemistry, 
molecular biology, cell biology, and medicine (137-141).  
An AFM uses a cantilever with a tiny sharp tip at the end to scan over a sample surface. It uses 
various forces that develop when two objects are brought within nanometers of each other. 
Typically, an AFM can work either when the probe is in contact with a surface, causing a repulsive 
force, or when it is a few nanometers away, where the force is attractive. As the tip lowers to the 
surface, the close-range attractive forces between the surface and the tip make the cantilever to 
bend towards the surface. However, as the cantilever is brought even closer to the surface 
increasingly repulsive forces cause the cantilever to bend away from the surface (142-144). An 
AFM has a Z-scanner (piezo) that moves the cantilever up and down, an XY-scanner (piezo) that 
moves the sample back and forth underneath the cantilever and a position detector (PD) that 
records the bending of the cantilever. The position sensor works by tracking a laser beam that is 
reflected off the flat top, see Figure 1.1A (145). 
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Figure 1.1. The principle of AFM (145). (A) Schematic of the main components of an AFM 
device with working principles. (B) A schematic photodetector signal of the cantilever deflection 
recorded during a single molecule force spectroscopy (SMFS) curve together with the 
corresponding position of the cantilever and surface. 
 
AFM is most commonly used to determine the topography of a surface, which is the foundation 
of conventional AFM techniques, there is also a range of AFM variations, such as Kelvin Probe 
A 
B 
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Force Microscopy (KPFM, which is a technique that measures the potential difference between a 
sample and the AFM tip) (146, 147), magnetic force microscopy (MFM, the tip detects the 
magnetic interactions at the surface of the material and builds up a spatial distribution map of the 
material’s magnetic structure) (148), and dual-probe AFM (DP-AFM, two independent probes 
operating in a common workspace enabling two AFM operations to be carried out simultaneously) 
(149-151).  
AFM has become a widely used technique due to its high resolution especially to the molecular 
level of biology samples (152). The increasing use of AFM in biology and medicine is a driving 
factor of its rapid growth (153). Not only the surface topography of cells can be imaged by AFM 
(154), but changes in the biophysical properties of the cell membrane such as cell stiffness and 
adhesion can be measured as well (155-163). Samples can be directly analyzed in their natural 
physiological conditions, without the need for any sample preparation, saving a lot of research 
time. 
Recent advances in AFM involve usage in cancer research and diagnosis (164, 165). AFM can 
detect the changes and differences between single cancerous and non-cancerous cells, which 
can allow for early diagnosis and treatment of cancer. AFM can also reveal the structure and 
function of cancerous cells by identifying the mechanisms involved in their spreading and the 
interaction processes between cells (166). 
AFM is capable of testing the interactions of drugs with receptors as well as testing the contact of 
the drug candidate with target cell membranes. Due to the non-destructive feature of AFM, it can 
be used to look at soft samples under controlled environmental conditions, which then serves as 
a unique foundation for the in vitro development of novel drug delivery systems. Enzyme 
hydrolysis visualization can also be done by the phase imaging mode of the AFM which provides 
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thorough qualitative and quantitative evaluation of pharmaceutical formulations. AFM is currently 
the only available technique that is capable of measure forces in the pN range. 
In this study, we utilized a MFP-3D-BIO AFM from Asylum Research (Figure 1.2). It is mounted 
on top of an inverted microscope, which allowed visualization of the RBCs throughout 
experiments. Two kinds of silicon nitride probe were used. One consisting of triangle cantilevers 
which have tiny pyramid tips at the end (Figure 1.3), was used for the single molecule force 
spectroscopy (SMFS, Figure 1.1B). The other has tipless triangle cantilevers (Figure 1.4) and was 
used for the single cell force spectroscopy (SCFS, Figure 1.5). 
 
Figure 1.2. MFP 3D-BIO AFM. Labeled components of the AFM atop a Zeiss optical inverted 
microscope (167). 
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Figure 1.3. AFM probe with triangle cantilevers and pyramid tips (168). (A) Schematic of 
triangle cantilevers. (B) Schematic of a tip.  
 
   
Figure 1.4. AFM probe with triangle tipless cantilevers (169).  
 
 
Figure 1.5. Schematic of a single cell force spectroscopy (SCFS) experiment.  
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SMFS 
SMFS enables detection of single adhesion receptors on the RBC surface via measurement of 
the unbinding events between receptors and the ligand protein attached to the tip of an AFM 
cantilever, see Figure 1.1B. 
SCFS 
SCFS is capable of measuring adhesion of an entire cell to a protein- or cell-functionalized 
substrate, see Figure 1.5. A single cell is captured by a tipless cantilever and relocated to the 
protein- or cell-functionalized region where approaching and retracting force cycles are performed. 
 
1.4. Objectives 
The objectives for subsequent chapters are outlined as following. 
Chapter 2. Regulation of Active ICAM-4 on Normal and Sickle Cell Disease RBCs via AKAPs Is 
Revealed by AFM 
The in vitro technique of single-molecule force spectroscopy was applied to investigate the effects 
of subcellular cAMP-PKA signaling pathway and AKAPs on ICAM-4 receptor expression on 
normal and SS-RBCs. Human normal and sickle RBCs adhere to endothelium largely through the 
ICAM-4 receptor which is implicated in VOEs in SCD and activated through the cAMP signaling 
pathway. We measured the unbinding force between ICAM-4 on the RBC and αvβ3 attached to 
the AFM probe. We showed that the number of active ICAM-4 receptors on normal RBCs is not 
significantly different from that of SS-RBCs. In addition, we showed that epinephrine, a 
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catecholamine that binds to the β-adrenergic receptor and activates the cAMP-PKA dependent 
pathway, caused a significant increase in the frequency of active ICAM-4 receptors in both normal 
and SS-RBCs. However, the unbinding force between ICAM-4 and the corresponding ligand αvβ3 
remained the same. Furthermore, we demonstrated that forskolin (FSK), an adenylyl cyclase (AC) 
activator, significantly increased the frequency of ICAM-4 receptors on normal and SS-RBCs 
confirming that the activation of ICAM-4 is regulated by the cAMP-PKA pathway. Furthermore, 
we illustrated that A-kinase anchoring proteins (AKAPs) play an essential role in ICAM-4 
activation. The findings might be of clinical importance in the context of drug development for the 
prevention and treatment of VOE in SCD. 
Chapter 3. Valsartan Impedes Epinephrine-induced ICAM-4 Activation on Normal, Sickle Cell 
Trait and Sickle Cell Disease Red Blood Cells 
Abnormal RBC adhesion to endothelial αvβ3 plays a crucial role in triggering vaso-occlusive 
episodes in SCD. It has been demonstrated that in human embryonic kidney 293 cells, mouse 
cardiomyocytes, and COS-7 cell lines, the β-adrenergic and renin-angiotensin systems are 
interrelated and that there is a direct interaction and cross-regulation between β-AR and 
angiotensin II type 1 receptor (AT1R). Selective blockade of AT1R reciprocally inhibits the 
downstream signaling of β-ARs. Similar to the inhibition observed in the presence of a β-AR-
blocker. We made a hypothesis that this mechanism is active in RBCs. Through SMFS, we 
studied the effect of valsartan, an AT1R blocker, on the surface density of active ICAM-4 receptors 
on normal, sickle cell trait, and homozygous sickle RBCs. We found that pretreatment of RBCs 
with valsartan significantly impeded the activation of ICAM-4 receptors induced by epinephrine. 
This trans-inhibitory effect of valsartan may lead to novel pharmacological approaches for the 
prevention and treatment of vaso-occlusive crisis in SCD. 
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Chapter 4. Influence of Clinical Chemotherapeutic Agents on the Activation of RBC ICAM-4 
Adhesion Receptors Varies Due to Race and SCT Carrying Status 
Clinical disparities have been observed between African-American and white females. African-
Americans experience higher rates of adverse events during chemotherapy, particularly among 
breast cancer patients, they have more than 10% lower breast cancer survival than white females, 
and this difference persisted over time. This suggests inherited host factors may contribute to 
differential outcomes. An unstudied genetic trait in cancer outcomes are hemoglobinopathies, 
particularly SCT which is estimated to occur in 8-10% of African-Americans. SMFS was employed 
to detect the ICAM-4 expression on RBCs from three groups of participants: white female with 
wild-type hemoglobin (WFWT), black female with wild-type hemoglobin (BFWT), and black female 
sickle cell trait (BFSCT) with and without the administration of two chemotherapeutic agents, 
cyclophosphamide (CYP) and daunorubicin (DNR). We found that both drugs did not affect the 
ICAM-4 expression on WFWT-RBCs. CYP only significantly increased the ICAM-4 expression on 
BFWT-RBCs. In contrast, DNR only increased significantly the ICAM-4 expression on BFSCT-
RBCs. The findings suggest race and SCT carrying status might be critical factors in choosing 
chemotherapy drugs for different patients. 
Chapter 5.  Further Approaches to Understand RBC Biophysics 
A cell is neither a perfect elastic solid nor a perfect viscous liquid. Thus, in addition to Young’s 
modulus describing only the stiffness, a complex modulus consisting of both elastic and viscosity 
modulus would be a more accurate indicator for the mechanical properties of cells. Here, more 
attempts were made to further understand RBC biophysics. AFM generated time-dependent 
loadings were applied to RBC membrane and the cell responses were recorded and analyzed. 
The results indicated the complex modulus changes more rapidly in the high-frequency domain 
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than in the low-frequency domain. Furthermore, hypoxia could significantly alter the RBC stiffness 
and adhesion properties. 
 
1.5. Rationale 
RBC abnormal cytoadhesion is known to play a significant role in the genesis of vaso-occlusion 
in SCD. In addition, the degree of RBC adhesion has been shown to correlate with clinical severity 
of VOEs (65, 170). Studies using a variety of adhesion assays including micropipetting and 
perfusion chambers revealed that SS-RBCs adhere to endothelial cells, progressively inducing 
endothelial injury and inflammation contributing to vaso-occlusive events. ICAM-4 receptor on 
RBC binding with high affinity specifically to endothelial integrin αvβ3 is a major mediator to RBC 
cytoadhesion with endothelium. However, the mechanism underlying the abnormal adhesion is 
not fully understood. The clinical management of SCD is still basic and in great need for 
improvement, given the facts that only two-thirds of patients respond favorably to the only drug 
Hydroxyurea, blood transfusion and bone marrow transplant limitedly apply to selective patients. 
Therefore, substantial work is demanded to better understand and manage RBC cytoadhesion, 
in an effort to develop better therapeutic methods for the prevention and treatment of VOEs. 
ICAM-4 activation is mediated at least partially through the cAMP-PKA signaling pathway and 
may involve in cross-talk between the β-adrenergic receptor (β-AR) and angiotensin type 1 
receptor (AT1R). We employed an in vitro technique, single-molecule force spectroscopy (SMFS) 
based on AFM, to study human normal, SCT-, and SCD-RBC adhesion in physiological conditions. 
SMFS enables measurement of the unbinding force between ICAM-4 and αvβ3, the 
intermolecular force in pN range. Most importantly, SMFS enables detection of single ICAM-4 
molecules on the RBC surface, revealing the distribution and population of the active adhesion 
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receptors with and without the presence of biomedical reagents. By studying RBC adhesion using 
SMFS, we expect a significant impact on identifying potential targets and reagents for anti-
adhesive therapies to prevent and treat VOEs in SCD, providing supporting data for preclinical 
researches and clinical trials. 
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Chapter 2. Regulation of Active ICAM-4 on Normal and Sickle Cell Disease RBCs 
via AKAPs Is Revealed by AFM 
2.1. Introduction 
Sickle cell disease (SCD) is a blood disorder due to a recessively inherited point mutation 
occurring in the beta-globin gene, giving rise to abnormal hemoglobin (HbS) which, in 
deoxygenated conditions, polymerizes to form stiff filaments (60-62). This causes distortion to the 
shape of the RBC from biconcave to "sickled". Because of their distorted shape, RBCs carrying 
the defective hemoglobin HbS are called sickle RBCs (SS-RBCs). In addition to the irregular 
shape, SS-RBCs are stiffer, more viscous, and show higher adhesion than normal (wild-type) WT-
RBCs to other RBCs, platelets, leukocytes, and to the endothelium (61, 63-67). Abnormal SS-
RBC adhesion leads to delayed microvascular passage of deoxygenated RBCs inducing sickling 
and entrapment of RBCs, a key trigger of vaso-occlusive episodes (VOEs) which are the 
pathophysiologic hallmark of SCD (74). In addition, the degree of RBC adhesion has been shown 
to correlate with clinical severity of VOEs (65, 170).  
Work from others and us (74, 171, 172) has demonstrated that increased SS-RBC adhesion is 
due to enhanced expression of functional adhesion receptors on the RBC membrane. RBC 
receptor activation is dependent upon intracellular signaling pathways (5) that can be activated 
by extracellular stimuli. One such pathway is cAMP-PKA which can be activated by epinephrine, 
a catecholamine, which binds to G protein-coupled receptor (74, 172, 173). It has been shown 
that the cAMP-PKA pathway directly regulates the activation of the basal cell adhesion 
molecule/Lutheran (BCAM/Lu) on the RBC surface (172, 174). These BCAM/Lu receptors in turn 
bind to laminin-alpha-5, a component of the endothelial subcellular matrix (174). In addition, 
studies using a variety of adhesion assays including micropipetting and perfusion chambers 
 18 
 
revealed that SS-RBCs adhere to endothelial cells (170, 175), inducing endothelial injury and 
inflammation likely contributing to vaso-occlusive events (65, 170, 176-178). Zennadi et al. (66) 
further showed that intercellular adhesion molecule-4 (ICAM-4) was the primary receptor 
mediating the adhesion of SS-RBCs to endothelial cells and that the ligand for the ICAM-4 
receptor was the endothelial αvβ3 integrin (66, 179, 180). They also identified that epinephrine 
can stimulate the activation of ICAM-4 at least partially via the cAMP-PKA dependent signaling 
pathway. Specifically, epinephrine stimulates RBC β2-adrenergic receptors (β2-ARs) through 
activation of the α subunit of the associated G protein (Gαs) by exchanging its bound guanosine 
diphosphate (GDP) to guanosine triphosphate (GTP) (181, 182). The activated Gαs, together with 
GTP, then dissociates from the β and γ subunit to further stimulate adenylyl cyclase (AC) (183, 
184). AC catalyzes the conversion of adenosine triphosphate (ATP) to cAMP which then activates 
PKA (172, 185). PKA, in turn, phosphorylates ICAM-4. The cAMP-PKA pathway is described in 
appendix 2.A (2.A.1 and Figure 2.A.1).  
Our group first demonstrated that scaffold proteins termed A-kinase anchoring proteins (AKAPs) 
are critical for mediating adherence of RBC BCAM/Lu receptors to laminin (172). The AKAP family 
includes ~50 structurally diverse, but functionally similar scaffolding proteins which contain (i) a 
common PKA-anchoring domain that binds to the regulatory subunit of PKA (186-188) and (ii) a 
unique subcellular targeting domain guiding the PKA-AKAP complex (181, 189, 190). AKAPs 
anchor PKA to specific subcellular sites, thereby guiding PKA activity towards specific locations 
in the cell, such as the plasma membrane (191) where PKA can alter the phosphorylation state 
of neighboring RBC receptors (186). It is postulated that it is by this mechanism that AKAPs 
mediate cAMP-PKA dependent activation of RBC adhesion receptors (172). 
In this study, we extend our work to investigate the effects of the cAMP-PKA pathway 
manipulation on (i) the binding between ICAM-4 and αvβ3 and (ii) the expression of active ICAM-
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4 receptors on the membrane of both WT-RBCs and SS-RBCs. We also investigate whether 
AKAPs play a role in ICAM-4 activation. We implement single molecule force spectroscopy 
(SMFS) by using an atomic force microscope (AFM) which allows for the detection of single 
functional receptors on cells and at the same time measurement of the unbinding force between 
a receptor and the corresponding ligand (172, 192-198). It also allows detection of variations in 
the collective frequency (CF) of active ICAM-4 receptors on the RBC membrane. We use several 
biochemical reagents that manipulate the cAMP-PKA pathway and the AKAP-PKA complex to 
regulate ICAM-4 activation. In addition, we used confocal microscopy to corroborate our AFM 
results. 
Our experiments confirmed, at the single molecule level, that the activation of the ICAM-4 
receptors depends upon the cAMP-PKA pathway. We found that the surface expression of active 
ICAM-4 receptors in WT-RBCs and in SS-RBCs are not significantly different using both SMFS 
and confocal microscopy. We also showed that epinephrine increased the expression of active 
ICAM-4 receptors in RBC samples from both healthy donors and SCD patients. Importantly, we 
demonstrated that this activation is mediated by AKAPs. In addition, we found that while the CF 
of active ICAM-4 receptors was modulated via the cAMP-PKA pathway, the mean value of the 
unbinding force between active ICAM-4 and αvβ3 did not change even at higher surface 
expressions of active ICAM-4. This means that activation of ICAM-4 did not alter the unbinding 
force and that nanoclusters of ICAM-4 receptors were not formed in detectable numbers. This 
result along with the finding that epinephrine activates ICAM-4 in both WT- and SS-RBCs 
contrasts results based on flow chamber assays where epinephrine did not significantly increase 
ICAM-4-dependent adhesion on WT-RBC. The findings of this work might be of clinical 
importance in the context of drug development for prevention and treatment of VOE in SCD by 
hindering enhanced adhesion events between RBCs and the endothelium by introducing 
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biomedical reagents that not only act along the cAMP-PKA pathway but also on the AKAP-PKA 
complex. 
 
2.2. Materials and methods 
Human subjects and blood preparation 
Our clinical protocol was approved by the Institutional Review Boards of UCONN Health and 
UCONN-Storrs. Inclusion/exclusion criteria for healthy volunteers: Healthy volunteers were 
eligible provided they were at least 7 years old and had a normal hemoglobin electrophoresis. 
Healthy volunteers were excluded from the study if they were pregnant, breast-feeding, or within 
3 months post-partum, used anti-lipid therapy within the previous week, were taking an 
investigational drug, or received a blood transfusion within the previous 3 months.  
Inclusion/exclusion criteria for homozygous SCD (SS) patients: SCD patients were included in the 
study if they had documented homozygous SS disease, were at least 7 years old, and were in 
steady state. Steady state was defined as not having received parenteral opioid administration in 
the last 4 weeks, had pain no greater than the usual daily level for 4 weeks, and no increase in 
usual non-parenteral opioid medication utilization in the past 4 weeks. SCD patients were 
excluded from the study if they were pregnant, breast-feeding, or within 3 months post-partum, 
used anti-lipid therapy within the previous week, were taking an investigational drug, treated with 
hydroxyurea (HU), or received a blood transfusion within the previous 3 months. HU treatment 
was an exclusion criterion because HU has been shown to affect RBC adhesion to laminin by 
inhibiting phosphorylation of BCAM/Lu (172, 199) and we reasoned that HU might act in a similar 
way to inhibit activation of ICAM-4. None of the SCD subjects had chronic organ damage. 
Demographic and clinical characteristics of subjects are found in Table 2.1.   
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Table 2.1. Demographic and clinical characteristics of the blood donors 
SCD Patient  Healthy Volunteer 
  
n=4 
  
n=3 
 
 
Age, mean, SD 
 
Gender, n, %  
     Male 
 
Race, n, % 
     African American 
    
   
Genotype, n, % 
     HbSS 
 
Hemoglobin, g/dL, mean, SD 
 
Leukocyte count, K/μL, mean, SD 
 
Platelet, K/μL, mean, SD 
 
Neutrophil, %, mean, SD 
 
Reticulocytes, %, mean, SD 
 
LDH, U/L, mean, SD 
 
 
26 (5) 
 
 
4 (100) 
 
 
4 (100) 
 
 
 
4 (100) 
 
9 (0) 
 
14 (2) 
 
502 (181) 
 
53 (15) 
 
13 (5) 
 
444 (66) 
 
 
Age, mean, SD 
 
Gender, n, %  
     Female 
 
Race, n, % 
     African American 
     White 
 
Genotype, n, % 
     HbAA 
      
Hemoglobin, g/dL, mean, SD 
 
Leukocyte count, K/μL, mean, SD 
 
Platelet, K/μL, mean, SD 
 
Neutrophil, %, mean, SD 
 
 
40 (3) 
 
 
3 (100) 
 
 
2 (67) 
1 (33) 
 
 
3 (100) 
 
13 (1) 
 
6 (2) 
 
284 (64) 
 
57 (10) 
 
Blood samples were obtained from fresh-drawn, heparin-anticoagulated venous blood of eligible 
volunteers after obtaining informed consent. Whole blood was centrifuged at 145 ×g for 5 min at 
4℃ to separate the RBCs. The plasma and buffy coat were extracted and discarded. Then, the 
remaining RBCs were washed three times with Alsever’s solution and stored at 4℃ for up to seven 
days. We note that the experiments were performed in normal not-hypoxic conditions. The reason 
is that hypoxia (65) and the consequent change in the viscoelastic properties of SS-RBCs (200) 
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may play a role in the variation RBC adhesion adding another parameter to the main focus of this 
paper which is the cAMP-PKA pathway. We also note that in SS patients the reticulocyte count 
average was 13 ± 5 % (see Table 2.1), increased compared to healthy donors where the 
reticulocyte count is typically close to 0.5-2% (201). In our experiments, we chose to test only 
RBCs having the characteristic biconcave shape in order to exclude reticulocytes, which typically 
have irregular shapes in our samples (see 2.A.2 and Figure 2.A.2).  
 
Ligand and reagents 
Human integrin αvβ3 protein (100 μg/mL, diluted with PBS) was obtained from Millipore (Billerica, 
MA). Alsever’s solution, epinephrine (16.39 nM, reconstituted in Alsever’s solution), forskolin (FSK; 
0.49 μM, reconstituted in DMSO), and bovine serum albumin (BSA; 100 μg/mL, reconstituted in 
PBS) were purchased from Sigma-Aldrich (St. Louis, MO). St-Ht31 inhibitor peptide and St-Ht31P 
control peptide (both 81.97 nM, reconstituted in Alsever's solution) were purchased from Promega 
(Madison, WI). RBCs were treated with the reagents above at 37o for 30 min unless otherwise 
indicated. 
 
AFM cantilever probe functionalization 
Soft silicon nitride cantilevers with silicon nitride tips were purchased from Bruker Nano Inc. 
(Camarillo, CA). The tip height is between 2.5 and 8 μm and the nominal tip radius is 20 nm. The 
nominal spring constant of the applied cantilever is 30 pN/nm. The actual spring constant under 
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the experimental condition (in Alsever’s solution at 37℃) was calculated by a thermal noise based 
method (202, 203). 
Glutaraldehyde functionalization: Silicon nitride probes (Bruker AFM Probes, Camarillo, CA) were 
first amino-functionalized with 2% v/v 3-aminopropyltriethoxysilane (APTES) in acetone (Sigma 
Aldrich, St. Louis, MO) for 10 min, then rinsed with deionized (DI) water. Probes were soaked in 
0.5% v/v glutaraldehyde (solution in DI water) for 30 min then rinsed again with DI water and 
incubated in 100 μg/mL αvβ3 solution. After 30 min, the probes were rinsed with DI water and 
immersed in 100 μg/mL BSA for 1 min to block the remaining aldehyde groups. Probes were 
stored in PBS at 4℃ and used within three days. 
Acetal-PEG-NHS-αvβ3 functionalization: Silicon nitride probes were functionalized with αvβ3 via 
acetal-PEG-NHS (Institute of Biophysics, Johannes Kepler University, Linz, Austria) following 
manufacturer instructions (http://www.jku.at/biophysics/content). 
 
AFM setup and data recording 
Experiments were performed using the MFP-3D-BIO AFM (Asylum Research, Santa Barbara, 
CA), which was mounted on an inverted microscope (Zeiss Axiovert A1). Using the microscope, 
we were able to position the AFM cantilever on a chosen RBC (Figure 2.1 A) that was less than 
10 μm in diameter and possessed an explicit circular biconcave shape indicative of RBC maturity 
and functionality. RBCs were pretreated with specific biomedical reagents and incubated at 37℃ 
(30 min for epinephrine, FSK; 2h for St-Ht31, St-Ht31P). For each reagent, five RBCs were tested 
from each subject. RBCs were seeded in a glass bottom petri dish (Ted Pella, Inc., Redding, CA) 
which was pre-treated with 1 mg/mL poly-L-lysine solution (Sigma-Aldrich, St. Louis, MO) for 15 
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min at room temperature. At these conditions, RBC adhered slightly to the substrate while they 
maintained their biconcave shape. During the cantilever retraction, RBCs were not pulled off the 
substrate as we could clearly determine via the inverted microscope. 
 
Figure 2.1. Single molecule force spectroscopy. (A) Optical microscopy image showing the 
shadow of an AFM cantilever and a representative human RBC. The scale bar corresponds to 
10 μm. (B) Force curve plot exhibiting an unbinding event. The red curve represents the 
approach of the cantilever to the RBC surface membrane while the blue curve represents the 
retraction of the cantilever from the RBC. The sharp change in the magnitude of the retraction 
force signifies the unbinding force. 
 
Adhesive interactions were quantified by recording force-distance curves at 32×32 points, 
distributed in a 1μm2 area of the RBC membrane, between an αvβ3-functionalized cantilever and 
ICAM-4 receptors expressed on the RBC membrane. Each curve recorded a complete approach 
and retraction cycle. We have shown that measurement at 1024 points uniformly distributed in a 
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1μm2 area gives a representative result for the specific tested RBC. We note that because AFM 
experiments (and the following data processing) are time-consuming and often detrimental to 
tested cells, we have standardized the optimum scanning area for SMFS  experiments on RBCs 
to be 1 μm2 in (167). The AFM data were processed using our in-house developed code named 
FRAME (Force Review Automation Environment) (204). An unbinding force was determined as 
the magnitude of the abrupt drop to zero on the retraction force-displacement curve with a rupture 
event (Figure 2.1B). The approach and retraction speed was 800 nm/s which gave a nominal 
loading rate of 24,000 pN/s. At this speed, the unbinding measurements were not significantly 
affected by hydrodynamic forces (205). A specific trigger point/threshold was set to control the 
indentation depth and to ensure that the same nominal maximum force was applied to each RBC. 
The corresponding probe travel distance was ~200 nm which meant the probe was in contact with 
the RBC membrane for ~1/4 s before retraction. We only considered the interactions for which 
the effective spring constants (keff) were less than 10 pN/nm which, in combination with the 
retraction speed, ensures that the influence of keff is not significant for SMFS experiments (206). 
The effective spring constants were obtained from the slopes of the curves adjacent to the 
unbinding force drops (207, 208). The unbinding forces were plotted as a force map displaying 
the spatial distribution of the active ICAM-4 receptors on the RBC surface (Figure 2.2A). The color 
of each spot represented the value of the unbinding force obtained from the corresponding 
retraction path.  CF% is defined as the percentage of all unbinding events divided by the total 
number of measurements, which is 32x32=1024 for each cell multiplied by the number of tested 
cells for each subject’s blood sample. CF represents the population of active ICAM-4 receptors 
capable of binding to αvβ3. This approach allowed observation of changes in the force maps due 
to modulation of the CF of activated ICAM-4 receptors in the presence of biochemical reagents 
that interfere with the cAMP-PKA pathway and the AKAP-PKA complex.  
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Figure 2.2.  Distribution of active ICAM-4 receptors and unbinding force between αvβ3 
and ICAM-4. (A) Representative force maps from a 1μmx1μm area of an individual RBC (i) at 
baseline, (ii) treated with 16.39 nM epinephrine, and (iii) treated with 16.39 nM epinephrine and 
1.29 μg/mL bath αvβ3 to block activated ICAM-4. Scale bars, 250 nm. Color scale as shown 
indicates the magnitude of the unbinding force. (B) Frequency distributions of unbinding forces 
between ICAM-4 and αvβ3 in WT-RBCs. (C) Box-and-whisker plot of the CF of active ICAM-4 
receptors on WT-RBCs. Data are shown as median with min and max whiskers and the mean 
denoted as a color dot. The ‘n’ on the x-axis indicates the total number of mature WT-RBCs 
analyzed in each group, obtained from the following numbers of human subjects: Baseline: 3 
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subjects; + Epinephrine: 3 subjects. + Epinephrine + bath αvβ3: 1 subject. Significance relative 
to baseline or between conditions is denoted as * for p<0.0001. (D) Frequency distributions of 
unbinding forces between ICAM-4 and αvβ3 in SS-RBCs. (E) Box-and-whisker plot of the CF 
of active ICAM-4 receptors on SS-RBCs. Data are shown as median with min and max whiskers 
and the mean denoted as a color dot. The ‘n’ on the x-axis indicates the total number of mature 
SS-RBCs analyzed in each group, obtained from the following numbers of human subjects: 
Baseline: 4 subjects; + Epinephrine: 4 subjects. + Epinephrine + bath αvβ3: 1 subject. 
Significance relative to baseline or between two conditions is denoted as * for p<0.0001. 
 
Binding specificity of αvβ3 ligands to ICAM-4 receptors 
It is known that in mature RBCs, ICAM-4 is the major receptor for the endothelial integrin αvβ3 
(171, 179). To show that our measurement technique is specific to αvβ3, we first performed 
experiments on RBCs from healthy volunteers to obtain the baseline CF of active ICAM-4 
receptors and unbinding forces between the αvβ3 ligand and ICAM-4 receptor. Figure 2.2A (i) 
shows a representative force map recorded during the surface scan. There are 32×32 pixels in 
each force map. The color of the pixels indicates the force values ranging between 0 and 100 pN 
according to the color scale shown in Figure 2.2A. We show that treatment of RBCs from healthy 
subjects with epinephrine, a catecholamine which binds to the β2-adrenergic receptor and 
activates the cAMP-PKA dependent pathway, significantly increases the CF of active ICAM-4 
receptors (Figure 2.2C) compared to baseline. When we first treated the sample with epinephrine 
and then with bath αvβ3, we saw a dramatic decrease in the CF of detected unbinding events 
compared to the CF measured when the sample was incubated only with epinephrine (Figure 
2.2A(iii), C), suggesting that αvβ3 in the bath blocked most of the active ICAM-4 receptors on the 
RBC membrane. In addition, we performed experiments with a cantilever treated with APTES, 
glutaraldehyde, and BSA but not with αvβ3 (non-functionalized cantilever). The recorded CF was 
negligible (0.62%) meaning that αvβ3 is indeed the functional protein on the cantilever tip (see 
2.A.3 and Figure 2.A.3). In addition, this measurement defined the background noise of the SMFS 
method for the specific assay described here. 
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Immunocytochemistry 
70µL of normal or sickle blood was added to assigned wells containing poly-D-lysine coated 
coverslips and incubated at 37°C for 15 minutes. Following incubation, cells were washed with 
Dulbecco’s PBS (dPBS, ThermoFisher Scientific, Waltham, MA) and incubated with 16.39nM 
epinephrine (Sigma-Aldrich, St. Louis, MO) or 1μL DI water carrier for 30 minutes at 37°C. 
1.29µg/mL human integrin αvβ3 protein (Millipore, Billerica, MA) was added to all the wells for 30 
minutes at 37°C followed by washing with dPBS. Cells were then fixed with 
2%Paraformaldehyde/4% Sucrose/PBS for 5 minutes at room temperature. After washing with 
dPBS and blocking with pre-block buffer (20mM phosphate buffer, pH 7.4, 5% normal goat serum, 
450mM NaCl) for 1 hour at 4°C, cells were incubated with mouse anti-integrin αvβ3 antibody 
(1:500, Abcam, Cambridge, MA, Cat# ab78289) primary antibody in pre-block buffer overnight at 
4°C.   
The next day, cells were incubated with pre-block buffer for 1 hour at 4°C and then incubated with 
goat anti-mouse Alexa Fluor 488 (1:500, Abcam, Cambridge, MA, Cat# ab150113) secondary 
antibody in the pre-block buffer for 2 hours in the dark. Cells were then washed with dPBS and 
coverslips were mounted on glass slides using prolong Diamond (ThermoFisher Scientific, 
Waltham, MA) mounting media. 
 
Image acquisition 
All images were taken on a laser-scanning Leica SP8 (Leica Microsystems, Wetzlar, 
Germany) confocal microscope. Z-stacks were taken with a step size of 0.25μm. Imaging 
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conditions for all the paraformaldehyde-fixed cells were as follows: 63X oil immersion lens was 
used to view the cells; the pinhole size was set at 1 airy unit; the raw images were exported as .tiff 
files and viewed on NIH Image J software. For all the acquired images, only brightness and 
contrast for the entire frame was adjusted on Image J and no singular section of the frame was 
modified in any way. 
 
Image quantitation 
Z-stacks from the same cell were projected using the Z-project function of Image J software. To 
quantify the fluorescence intensity of the green (active ICAM-4) channel, a region of interest (ROI) 
was chosen and the measurement analysis was set to yield the area, min and max pixel strength, 
integrated and raw density and mean grayscale value. The raw values were exported to Excel. 
The corrected total fluorescence (CTF) was calculated for the chosen ROIs for cells in different 
conditions. CTF is the resultant output of subtracting the mean background intensity over the 
chosen ROI from the integrated density for each ROI. 
 
Statistical analysis 
The unbinding forces between αvβ3 ligands and ICAM-4 receptors are reported using frequency 
(%) distribution which states the percentage of events whose unbinding forces are within each 
bin's width. We then compare the median values of the forces measured in experiments without 
and with treatment with different reagents. The zero force points are not shown because they 
would obscure the plots since their population is much larger than the population of unbinding 
events. CF% is related to the population of active ICAM-4 receptors and it is defined as the 
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percentage of all unbinding events divided by the total number of measurements, which is 
32x32=1024 for each cell multiplied by the number of tested cells for each blood sample. The CF 
and CTF results are reported as mean ± standard error (SE) and illustrated by box-and-whisker 
plots (GraphPad Prism, GraphPad Software, Inc.). They are compared using one-way analysis of 
variance (ANOVA) and the Tukey-Kramer post hoc test. The results are considered significant if 
p<0.05.  
 
2.3. Results and discussion 
Epinephrine increases the surface density of active ICAM-4 receptors on normal and SS-
RBCs but not the unbinding force between ICAM-4 and αvβ3. 
Epinephrine is a hormone whose action is mediated by the beta-adrenergic receptor, a seven-
transmembrane domain receptor that can activate guanine nucleotide regulatory binding proteins 
(G protein-coupled receptors) (209). It has been previously shown that activation of the cAMP-
PKA dependent pathway by epinephrine increases adhesion of sickle but not normal RBCs to 
endothelium via ICAM4-αvβ3 interaction (171). The experimental technique employed in these 
studies was based on the flow chamber assay which measures the overall RBC adhesion and 
not directly the population of functional adhesion receptors or the strength of interactions between 
ligand-receptor pairs. 
Here, we used the SMFS assay that, as established in our previous work (172, 173), can detect 
variations of the surface density of active adhesion receptors on the RBC membrane (i.e., CF %) 
and record unbinding forces between receptors and ligands. We scanned a 1μm2 area of 
individual RBC membranes with an AFM cantilever functionalized with αvβ3 to directly detect the 
 31 
 
population of active ICAM-4 receptors under different experimental conditions. We first tested 
RBCs from healthy volunteers (WT-RBCs) at baseline and after in vitro treatment with epinephrine. 
Force maps shown in Figure 2.2A (i, ii) clearly illustrate that epinephrine increases the CF of 
active ICAM-4 receptors. However, epinephrine had no effect on the median unbinding force 
(Figure 2.2B, Table 2.2) suggesting epinephrine only affects the activation of ICAM-4 receptors 
and not the strength of their interaction with αvβ3 ligand.  
Table 2.2. Unbinding forces between ICAM-4 and αvβ3 and collective frequencies of active ICAM-
4 receptors for WT-RBCs and SS-RBCs  
* There was not enough non-zero unbinding force data to generate an accurate median value. 
To establish a measure of the overall quantity of active ICAM-4 receptors, we calculated the CF.  
The results are reported in box-and-whisker plots in Figure 2.2C. We found that the mean value 
of the CF increased significantly from 7.1% in baseline experiments to 23.63% when the blood 
sample was treated with epinephrine (p<0.0001). This suggests that epinephrine triggers 
activation of ICAM-4 receptors on WT-RBCs probably via the cAMP-PKA pathway. 
Next, we tested RBCs obtained from volunteers with SCD (SS-RBCs). We measured the CF of 
ICAM-4 receptors with and without treatment with epinephrine. Similar to WT-RBCs, we found 
that the median unbinding force between ICAM-4 and αvβ3 did not significantly change (Table 
2.2, Figure 2.2D). The CF of ICAM-4 adhesion was measured to be 10.08±0.85% for SS-RBCs 
without epinephrine treatment, higher than in the case of WT-RBCs, although not significant 
 Unbinding force (median, pN) Collective frequency (mean ± SE, %) 
WT SS WT SS 
Test condition     
Baseline 24.59 23.59 7.10±1.26 10.08±0.85 
+epi 24.27 24.53 23.63±2.23 21.41±2.27 
+epi+bath αvβ3 * * 1.43±0.37 1.78±0.31 
+FSK 24.08 24.70 25.91±3.71 26.55±2.68 
+St-Ht31+FSK 27.45 26.09 7.80±2.16 9.22±1.52 
+St-Ht31P+ FSK  *  36.56±8.73 
+St-Ht31P 25.09 21.94 7.56±1.81 10.12±2.32 
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(p=0.06). Treatment of SS-RBCs with epinephrine increased the CF significantly to 21.41±2.27% 
(Figure 2.2E, p<0.0001, Table 2.2).  
Our results are in agreement with previous experimental results showing that epinephrine 
increases adhesion of SS-RBCs to endothelium (171). Moreover, our findings give additional 
information that this increase is due to the increased number of active surface ICAM-4 and not 
due to increased unbinding force between ICAM-4 and αvβ3. We note, however, that Zennadi et 
al. did not detect a significant effect of epinephrine on WT-RBC adhesion to human umbilical vein 
endothelial cells (HUVECs) (171). One reason for this discrepancy might be that they incubated 
blood samples with 20 nM epinephrine for only 1 min at 37 ˚ C while we incubated them with 16.39 
nM epinephrine for 30 min at 37 ˚C. Another possible explanation is that their method is not as 
sensitive to detect changes when the overall adhesion is low. They used intermittent flow 
conditions in a flow chamber and they reported the ratio of the number of RBCs adhered to 
HUVECs after exposure to flow conditions over the number of initially adherent RBCs before 
exposure to flow while we directly measured the surface density of ICAM-4 at the single molecule 
level. Cell-cell and cell-matrix adhesion may be influenced not only by the number of adhesion 
pairs between molecules expressed on the cells but also on mechanical properties of cells (200, 
210). Our results, based on SMFS, give direct evidence that the unbinding force between ICAM-
4 and αvβ3 did not change when the cells were incubated with epinephrine meaning that ICAM-
4 activation did not alter the interaction between ICAM-4 and αvβ3 and did not cause the formation 
of nanoclusters. We finally note that these conclusions cannot be drawn using methods that 
directly measure RBC adhesion such as microfluidics or single-cell force spectroscopy (SCFS). 
To validate the specificity of our measurements, we added αvβ3 to the bath solution. We expected 
the bath αvβ3 to bind to activated ICAM-4 receptors on the RBC membrane thereby inhibiting 
cantilever-bound αvβ3 from binding to ICAM-4 on the RBC surface. Indeed, binding significantly 
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decreased in both WT-RBCs (CF 23.63±2.23 vs. 1.43±0.37%, p<0.0001) and SS-RBCs (CF 
21.41±2.27 vs. 1.78±0.31%, p<0.0001) (Figure 2.2, Table 2.2). These results confirmed that 
indeed it is αvβ3 that binds to the receptors on the RBC membrane and not other substances 
attached to the cantilever such as glutaraldehyde. Since our AFM cantilever functionalization 
technique involves the use of glutaraldehyde (211, 212) to attach the αvβ3 molecules to the 
cantilever, we wanted to test if glutaraldehyde, with its inability to control the number of αvβ3 
molecules attached to the cantilever, would skew the results. To this end, we functionalized AFM 
cantilevers with αvβ3 via an acetal-PEG-NHS linker, instead of glutaraldehyde, which guarantees 
that the probability the AFM cantilever is functionalized with only one molecule is greater than 50% 
(213) (Figure 2.3A, B). As demonstrated in Figure 2.3, we probed SS-RBCs at baseline and we 
found that both functionalization methods gave almost identical results with respect to unbinding 
force (23.08 pN for the glutaraldehyde functionalization vs. 25.85 pN for the acetal-PEG-NHS 
functionalization, p = 0.8451), and CF (7.37±1.45% for the glutaraldehyde functionalization vs. 
8.44±1.75% for the acetal-PEG-NHS functionalization, p = 0.6943, data not shown). This result 
means that ICAM-4 receptors expressed on the RBC membrane do not form nanoclusters since 
the median values of the measured unbinding forces are similar in both techniques. If the 
receptors had formed nanoclusters then higher unbinding forces would have been recorded 
forming a second peak in the unbinding force histogram as it is the case in Abiraman et al. (198).    
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Figure 2.3. Comparison of ICAM4-αvβ3 unbinding forces measured using 
Glutaraldehyde-based vs. PEG-based AFM cantilever functionalization. (A) Schematic of 
Glutaraldehyde-αvβ3 functionalized tip probing ICAM-4 molecules on the RBC membrane. (B) 
Schematic of acetal-PEG-NHS- αvβ3 functionalized tip probing ICAM4 molecules on the RBC 
membrane. (C) Frequency distributions of unbinding forces between ICAM-4 and αvβ3 on SS-
RBCs for Glutaraldehyde-based (black) and PEG-base (red) AFM cantilever functionalization. 
The same samples were used in both methods (2 subjects, n=10). 
 
Confocal microscopy experiments confirm SMFS-based results 
We performed confocal microscopy experiments to image active ICAM-4 receptors on RBCs to 
further confirm our SMFS-based findings. Both WT-RBCs and SS-RBCs were incubated with 
αvβ3 (1.29µg/ml for 30 min) in order to tag active ICAM-4. The RBCs were then washed 
thoroughly to remove any unbound αvβ3, fixed and stained with an anti-αvβ3 antibody which 
labeled the αvβ3 bound to the active ICAM-4.  Alexa Fluor 488 was used to visualize active ICAM-
4. We found that, similar to our AFM experiments, there was no significant difference in active 
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ICAM-4 expression between WT-RBCs and SS-RBCs (Figure 2.4A-C, WT: corrected total 
fluorescence (CTF) = 9.72±0.63, n=16; SS: CTF= 11.79±0.47, n=16; p=0.794). 
 
Figure 2.4. Confocal microscopy results showing the active ICAM-4 receptors on RBCs. 
WT and SS-RBCs were incubated with 16.39nM epinephrine or 1μl DI water carrier, then 
incubated with αvβ3 to label active ICAM-4, fixed and stained with an anti-αvβ3 antibody which 
labeled the αvβ3 bound to active ICAM-4. Representative confocal microscopy images of (A) 
WT-RBC (n=16) and WT-RBC + Epinephrine (n=10) (B) SS-RBC (n=16) and SS-RBC + 
Epinephrine (n=16). (C) Box-whisker plots of the corrected total fluorescence of active ICAM-4 
receptors on WT-RBCs and SS-RBCs with or without epinephrine treatment. The data are 
represented as mean ± SE *, p=0.0339, **, p=0.0042, n.s., no significant difference (one-way 
ANOVA) (1subject). 
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However, when WT-RBCs and SS-RBCs were incubated with epinephrine (16.39nM for 30 min 
at 37ºC) prior to being fixed and stained with anti-αvβ3 antibody, we found a significant increase 
in active ICAM-4 expression compared to baseline in both cases (Figure 2.4A-C, WT:  CTF= 
16.29±1.91, n=10, p=0.033; SS: CTF= 17.01±0.92, n=16, p<0.0001). In addition to the confocal 
experiments, we performed AFM experiments on the same samples to compare the CF of 
unbinding events between WT- and SS-RBCs at baseline and when the cells were incubated with 
epinephrine. We found that there was no significant difference in the CF of unbinding events 
between WT- and SS-RBCs (p > 0.5) and the addition of epinephrine caused a significant 
increase in the CF of unbinding events compared to baseline in both WT- (p=0.035) and SS-
RBCs (p=0.01) (Figure 2.A.4). These results are in agreement with the results of the confocal 
microscopy experiments performed with the same samples and with the overall AFM results 
discussed in the first section.   
 
Activation of ICAM-4 on WT-RBCs and SS-RBCs is regulated by the cAMP-PKA dependent 
pathway 
It is known that epinephrine binding of the β-AR activates the cAMP-PKA dependent pathway. 
Furthermore, Zennadi et al. demonstrated that SS-RBC adhesion is regulated by the same 
pathway (171). Using SMFS, we tested at the single-molecule level if the increased CF of active 
ICAM-4 receptors on WT-RBCs and SS-RBCs is controlled by the cAMP-PKA pathway. We 
introduced pharmacologic regulation by using biomedical reagents that act along the cAMP-PKA 
pathway. We first pre-treated WT-RBCs with FSK (0.49 μM), an AC activator which strongly 
activates PKA. Compared to baseline, FSK-treated WT-RBCs exhibited no difference in unbinding 
force (24.59 vs. 24.08pN, p=0.26, Figure 2.5A, Table 2.2) but a significantly higher CF (7.10±1.26 
vs. 25.91±3.71%, p<0.0001, Figure 2.5B, Table 2.2).  In agreement with the results of WT-RBCs, 
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we detected similar unbinding force (23.59 vs. 24.70 pN, p=0.32, Figure 2.5C, Table 2.2) and 
significantly increased CF in SS-RBCs pre-incubated with FSK (0.49 μM) compared to baseline 
(26.55±2.68 vs. 10.08±0.85%, p<0.0001) (Figure 2.5D, Table 2.2). This indicates that the CF of 
active ICAM-4 receptors on WT- and SS-RBCs is regulated by the cAMP-PKA dependent 
pathway and that the strength of adhesive interactions is not affected. We also conclude that 
because the strength of unbinding forces did not significantly change, clustering of ICAM-4 
receptors was unlikely.  
 
Figure 2.5.  Unbinding forces between ICAM4 and αvβ3 and the number of active ICAM-
4 receptors with the absence and presence of FSK. (A) Frequency distributions of unbinding 
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forces between ICAM4 and αvβ3 in WT-RBCs in the presence of PKA activator FSK (0.49μM). 
(B) Box-whisker plots showing the CF of active ICAM-4 receptors on WT-RBCs in the presence 
of FSK. Significance relative to baseline is denoted as * such that p<0.0001. The ‘n’ on the x-
axis indicates the total number of WT-RBCs analyzed in each group, obtained from: Baseline: 
3 subjects; FSK: 3 subjects. (C) Frequency distributions of unbinding forces between ICAM-4 
and αvβ3 in SS-RBCs in the presence of FSK (0.49μM). (D) Box-whisker plots showing the CF 
of active ICAM-4 receptors on SS-RBCs in the presence of FSK. Significance relative to 
baseline is denoted as * such that p<0.0001. The ‘n’ on the x-axis indicates the total number of 
SS-RBCs analyzed in each group, obtained from: Baseline: 4 subjects; FSK: 4 subjects. 
 
ICAM-4 receptor activation is dependent on AKAPs 
It is known that the action of PKA is localized to specific sub-membrane domains through PKA 
binding to AKAPs (181, 189, 190). Based on this, we investigated if AKAPs, located in the RBC 
membrane, play a role in the PKA-dependent activation of ICAM-4 receptors. To examine this, 
we used St-Ht31, a membrane-permeable peptide (214) comprising a PKA-anchoring domain 
that inhibits the binding of PKA to AKAPs (215). As we discussed above, FSK activates AC, which 
in turn activates PKA and causes a significant increase in the CF of active ICAM-4 receptors on 
WT- and SS-RBCs. To demonstrate that ICAM-4 is activated via AKAPs, we incubated RBCs with 
St-Ht31 (2 hours) and FSK (30 min) sequentially. In this case, the CF of active ICAM-4 on WT-
RBCs was detected to be 7.80±2.16 % in contrast to 25.91±3.71% obtained when only FSK was 
applied (Figure 2.6A, p<0.0001, Table 2.2). Similarly, on SS-RBCs, CF was found to be 
9.22±1.52 % compared to 26.55±2.68 % when only FSK was applied (Figure 2.6B, p<0.0001, 
Table 2.2). To confirm that the decrease was not due to a direct interaction between St-Ht31 and 
FSK, we pretreated SS-RBCs with St-Ht31P control peptide which differs from St-Ht31 by 
isoleucine-to-proline substitutions and thus can no longer bind to PKA (215). We found that in this 
case, the CF increased significantly (36.56±8.73%, p<0.0001, Table 2.2) demonstrating that 
indeed St-Ht31 inhibits activation of ICAM-4. When WT- and SS-RBCs were incubated solely with 
the control peptide St-Ht31P, the CF was similar to untreated samples (7.56±1.81% for WT-RBCs 
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and 10.12±2.32% for SS-RBCs, Table 2.2).  These results suggest that inhibition of AKAP-PKA 
complex suppresses the activation of ICAM-4 receptors in both WT- and SS-RBCs. 
 
Figure 2.6.  Modulation of active ICAM-4 via AKAPs on the RBC membrane. Box-whisker 
plots of the CF of active ICAM-4 receptors on (A) WT-RBCs and (B) SS-RBCs for the reagents 
indicated on the x-axis. The ‘n’ on the x-axis indicates the total number of mature RBCs 
analyzed in each group, obtained from the following numbers of human subjects: (i) for WT-
RBCs, Baseline: 3 subjects; St-Ht31P: 3 subjects; St-Ht31 (81.97 nM) + FSK (0.49μM): 3 
subjects. (ii) For SS-RBCs, Baseline: 4 subjects; St-Ht31P: 4 subjects; St-Ht31 (81.97 nM) + 
FSK (0.49μM): 4 subjects; St-Ht31P (81.97 nM) + FSK (0.49μM): 1 subject. Significance relative 
to baseline or between conditions is denoted as * such that p<0.0001. 
 
2.4. Conclusions 
In this study, we investigated at the single-molecule level the modulation of the surface density of 
active ICAM-4 receptors on WT- and SS-RBCs using SMFS and confocal microscopy. While it 
was known that epinephrine acts via the cAMP-PKA pathway to modulate the overall adhesion of 
SS-RBCs to ECs, the mechanisms by which epinephrine acts at the single molecule level was 
not known. Here, we demonstrated that epinephrine increases the surface expression of active 
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ICAM-4 receptors in both WT- and SS-RBCs. Furthermore, we confirmed that the activation of 
ICAM-4 receptors is regulated via the cAMP-PKA pathway and importantly we determined for the 
first time that this activation is mediated by AKAPs. In addition, we showed that while the CF of 
active ICAM-4 receptors was modulated via the cAMP-PKA pathway the median value of the 
unbinding force between active ICAM-4 and αvβ3 did not change even at higher surface 
expressions of active ICAM-4. This means that activation of ICAM-4 did not alter the unbinding 
force between ICAM-4 and αvβ3 and that nanoclusters of ICAM-4 were not formed in detectable 
numbers. This result along with the finding that epinephrine activates ICAM-4 in both WT- and 
SS-RBCs contrasts results based on flow chamber assays showing that epinephrine did not 
significantly increase ICAM-4-dependent adhesion on WT-RBC. Overall, our data might be of 
clinical importance in the context of drug development for prevention and treatment of VOE in 
SCD since they suggest that adhesion of RBCs to endothelial cells can be modulated, especially 
during stress conditions, by the introduction of biomedical reagents acting along not only the 
cAMP-PKA pathway but also on the AKAP-PKA complex.  
 
2.5. Appendix 2.A 
2.A.1. cAMP-PKA dependent pathway and AKAPs  
One important mechanism of ICAM-4 activation is via the cyclic adenosine monophosphate-
protein kinase A (cAMP-PKA) dependent signaling pathway (Figure 2.A.1) which can be mediated 
by A-kinase anchoring proteins (AKAPs). Activation of RBC β2-adrenergic receptors (β2-ARs), 
induced by epinephrine, activates the α subunit of the associated G protein (Gαs) by exchanging 
its bound guanosine diphosphate (GDP) to guanosine triphosphate (GTP). The activated Gαs, 
together with GTP, then dissociates from the β and γ subunit to further stimulate adenylyl cyclase 
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(AC). AC (which can be directly activated, e.g. by forskolin) catalyzes the conversion of adenosine 
triphosphate (ATP) to cAMP which then activates PKA. A kinase anchoring protein (AKAPs) 
anchors PKA to specific sites on the plasma membrane where PKA can alter the phosphorylation 
state of neighboring ICAM-4 receptors thereby causing their activation. (See (183, 184, 186)). 
 
 
Figure 2.A.1. RBC cAMP-PKA dependent pathway. 
 
2.A.2. Reticulocytes 
Thiazole orange has been proved to be an ideal fluorescent dye for reticulocyte analysis due to 
its good quantum yield, enhancement of fluorescence with RNA, membrane permeability, simple 
staining procedure, and ability to count as many reticulocytes as new methylene blue and was 
therefore used to identify reticulocytes in the petri dish containing blood sample (216). The 
following protocol was employed: (1) Stock solution of 1 mg/mL Thiazole orange (purchased from 
Sigma-Aldrich, St. Louis, MO) in methanol was made. (2) The stock solution was diluted to 3×10-
7 M in phosphate-buffered saline. (3) RBCs were seeded on a glass bottom petri dish, as we do 
 42 
 
for adhesion measurements, then 1mL 3×10-7 M Thiazole orange solution was added and 
incubated at room temperature for 1h. (4) Cells were then observed under fluorescence 
microscopy to identify reticulocytes (Figure 2.A.2 A and B). As for the unstained control (Figure 
2.A.2 C and D), we followed the same protocol as described above but added PBS instead of 
Thiazole orange solution in step (3). 
The reticulocyte count of the tested sample was 11.3%. Figure 2.A.2 A and B are representative 
bright-field and fluorescent microscopy images respectively of Thiazole orange stained RBCs. 
They show a representative area which contained both reticulocytes (in colored circles) which 
were excluded from our measurement and biconcave RBCs which were tested (in green triangles) 
to detect unbinding events. Figure 2.A.2 C and D are representative bright-field and fluorescent 
microscopy images respectively of unstained RBCs. As expected we did not observe any 
fluorescence.  
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Figure 2.A.2. Differentiating reticulocytes using Thiazole orange. (A) Optical microscopy 
image of RBCs in Thiazole orange solution (B) Fluorescent microscopy image of RBCs in Thiazole 
orange solution. (C) Optical microscopy image of RBCs in PBS. (D) Fluorescent microscopy image 
of RBCs in PBS. The scale bar corresponds to 20μm. 
 
2.A.3. Results from the control experiments related to BSA coating of the probe 
Here, we compare the histograms of unbinding forces and CF box-whisker plots of unbinding 
events between SS-RBCs and a probe coated with αvβ3 and then with BSA versus a cantilever 
coated only with BSA. We found a negligible number of unbinding events for non-αvβ3 coated 
probes. 
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Figure 2.A.3. Comparison of adhesion between non-αvβ3 and αvβ3 coated probes. (A) 
Frequency distributions of unbinding forces between ICAM4 and αvβ3 in SS-RBCs for probes 
coated with αvβ3 and then BSA and for probes coated only with BSA and not with αvβ3. (B) Box-
whisker plots showing the CF of active ICAM-4 receptors on SS-RBCs from probes coated with 
αvβ3 and then BSA and for probes coated only with BSA and not with αvβ3 (p=0.0001). 
 
2.A.4. AFM experiments on the same samples as the confocal microscopy experiments 
 
Figure 2.A.4. SMFS adhesion results on the same samples as the confocal microscopy 
experiments. CF of the unbinding events at baseline and after treatment with epinephrine for the 
samples that were used in the confocal experiments shown in Figure 2.4. We found no significant 
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difference in CF between WT- and SS-RBCs at the baseline and between WT and SS-RBCs after 
treatment with epinephrine. We found significant difference in CF between WT-RBCs at baseline 
and after treatment with epinephrine and between SS-RBCs at baseline and after treatment with 
epinephrine. The results are in agreement with the results from the confocal experiments performed 
on the same samples. (* signifies p < 0.04). 
 
2.6. Appendix 2.B Measurements of Hydrodynamic drag force Fh on AFM cantilevers 
This appendix is from the Supporting information of the paper: Maciaszek, J. L., K. Partola, J. 
Zhang, B. Andemariam, and G. Lykotrafitis. 2014. Single-cell force spectroscopy as a technique 
to quantify human red blood cell adhesion to subendothelial laminin. Journal of Biomechanics 
47(16):3855-3861. 
Fresh, ethanol cleaned, previously non-functionalized cantilevers were displaced through 
Alsever’s solution and pressed onto a clean glass surface at eight different constant speeds: 
0.5μm/s, 0.8μm/s, 1.0 μm/s, 2.0 μm/s, 4.0 μm/s, 6.0 μm/s, 8.0 μm/s, and 10.0 μm/s. Ten sets of 
extension and retraction curves were obtained for each speed. Two types of cantilevers and five 
cantilevers per type were tested. The first cantilever type tested was a tipless silicon nitride 
cantilever with nominal spring constant of 80pN/nm and the second cantilever type tested was a 
silicon nitride cantilever with a pyramidal tip and a nominal spring constant of 30pN/nm. For 
each test, the cantilever was set to dwell for five seconds at the end of every approach-
retraction cycle in order to allow the cantilever to reach equilibrium before the new 
measurement cycle. The difference between the average resistance forces during approach and 
retraction corresponds to 2Fh, where Fh is the hydrodynamic drag force (217). Figure 2.B.1 A 
shows a characteristic approach-retraction recording of a tipless cantilever at the speed of 0.8 
μm/s. The difference between the recorded forces during the motion within the fluid is evident. 
Figure 2.B.1 B shows the measured hydrodynamic forces for the two types of cantilevers at the 
tested speeds. Table 2.B.1 gives the average recorded hydrodynamic forces for each case. At 
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0.8 μm/s, where all our adhesion experiments were performed, the hydrodynamic forces were 
approximately 4.33 pN for the tipless cantilever which was used for the SCFS experiments and 
3.0 pN for the cantilever with a tip that was used for the SMFS experiments. In both cases, the 
hydrodynamic forces are small compared to the measured unbinding forces. The unbinding 
forces were quantified as the abrupt change with respect to the retraction curve.  
Table 2.B.1. The speeds of the cantilevers and the corresponding average hydrodynamic drag 
forces 
Tipless cantilever (80 pN/nm) 
Speed (μm/s) 0.5 0.8 1 2 4 6 8 10 
Drag force (pN) 4.14 4.33 5.06 9.286 18.32 27.20 36.41 45.96 
Cantilever with tip (30 pN/nm) 
Speed (μm/s) 0.5 0.8 1 2 4 6 8 10 
Drag force (pN) 2.82 2.99 3.50 6.04 11.14 17.09 21.90 28.08 
 
 
 
Figure 2.B.1. Hydrodynamic drag forces on the AFM cantilevers. (A) A characteristic 
approach-retraction curve recorded during the motion at a constant speed of 0.8 μm/s of a 
tipless cantilever with a nominal stiffness of 80 pN/nm. (B) Variation of the hydrodynamic forces 
applied during the motion in Alsever's solution of a tipless cantilever and a cantilever with a tip 
at various constant speeds.    
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Chapter 3. Valsartan Impedes Epinephrine-induced ICAM-4 Activation on Normal, 
Sickle Cell Trait and Sickle Cell Disease Red Blood Cells 
3.1. Introduction 
In sickle cell disease (SCD), an inherited β-globin gene point mutation encodes abnormal 
hemoglobin (HbS), which under deoxygenated conditions polymerizes to form long stiff filaments 
deforming red blood cells (RBCs) from a biconcave to a sickle shape (60-62). Sickle cell trait (SCT) 
is a heterozygous state characterized by the presence of both normal hemoglobin (HbA) and HbS. 
While patients with SCD suffer increased mortality and often widespread chronic organ damage, 
individuals with SCT are generally asymptomatic and live a normal lifespan. However, under 
extreme conditions, such as hypoxia, acidosis, and dehydration, individuals with SCT can develop 
a syndrome resembling SCD with vaso-occlusive sequelae (119, 120). 
It has been shown that sickle RBCs (SS-RBCs) are stiffer and more viscous than normal (wild-
type, WT) RBCs (63, 167, 172, 173, 218, 219). In addition, SCT-RBCs and SCD-RBCs are more 
adhesive than WT-RBCs due to higher activation of surface receptors (64-67). Increased RBC 
adhesion, enhanced stiffness, and abnormal shape contribute to the entrapment of RBCs in the 
blood vessels and impediment of blood flow triggering painful vaso-occlusive episodes (VOEs),  
the hallmark of SCD (74).  
Human red blood cells (RBCs) express a large number of adhesion receptors on their membrane 
such as basal cell adhesion molecule/Lutheran (BCAM/Lu) and intercellular adhesion molecule-
4 (ICAM-4), both of which are known to play a significant role in the genesis of vaso-occlusion in 
SCD (66, 74, 171, 172, 174, 220, 221). BCAM/Lu and ICAM-4 bind with high affinity specifically 
to laminin-α-5, a component of the endothelial subcellular matrix, and to endothelial integrin αvβ3 
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respectively, and are the primary receptors that mediate the adhesion of SS-RBCs to endothelium. 
Surface receptors can be activated through certain intracellular signal pathways (171, 172, 174, 
181, 222). Previous research shows that BCAM/Lu and ICAM-4 receptor activation is mediated 
via the cyclic adenosine monophosphate-protein kinase A (cAMP-PKA) pathway (66, 172, 174, 
223). As shown in Figure 3.1, stimulation of β2-adrenergic receptors (β2-ARs) with an agonist, 
such as epinephrine, a catecholamine commonly secreted due to physical stress, can cause 
dissociation of the alpha subunit of its coupled Gs protein, which then activates adenylyl cyclase 
(AC) (181-184). AC catalyzes the conversion of adenosine triphosphate (ATP) to cAMP which 
then activates PKA (172, 185). A kinase anchoring proteins (AKAPs) anchor PKA to specific 
intracellular sites on the RBC membrane where PKA can alter the phosphorylation state of 
neighboring RBC adhesion receptors thereby causing their activation (172, 223). Propranolol, as 
a β-AR antagonist, has been shown to be effective in vivo both in mice and in humans to reduce 
epinephrine-stimulated SS-RBC adhesion and to prevent vaso-occlusion in mice (105). These 
findings suggest that RBC receptor blockers may have a role as anti-adhesive therapy for SCD. 
 
Figure 3.1. RBC cAMP-PKA-dependent pathway and AT1R vs β-AR dimer/complex. 
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The adrenergic system and the renin-angiotensin system are interrelated (Figure 3.1) (224). 
Angiotensin II (Ang II) is an octapeptide hormone and neurotransmitter that plays a significant 
role in the regulation of renal, cardiovascular, and endocrine function (225). Ang II exerts its 
biological effects through signaling pathways activated upon binding to two receptors, Ang II type 
1 receptor (AT1R) and Ang II type 2 receptor (AT2R), and relying mainly on binding to AT1R (226).  
AT1R, similarly to β2-AR, is a member of the seven-transmembrane-domain, the superfamily of 
G protein-coupled receptors (GPCRs), and it mediates most of the pathophysiological effects of 
Ang II, including vasoconstriction, inflammation, growth, and fibrosis. Ang II binding to the AT1R 
results in coupling of G proteins (Gq/G11and/or Gi/Go, G12, and G13) to the C-terminus of the 
receptor and to stimulation of several intracellular/cytoplasmic signaling pathways (226-229). 
Although receptors in the GPCR superfamily were initially believed to function as monomeric 
entities, mounting evidence suggests that they are oligomers and function either through 
interactions with identical units (homodimers) or with other GPCRs (heterodimers) (230-235). In 
addition, many identified homodimers and heterodimers of GPCRs have different ligand binding 
(236, 237), signaling (238, 239) and trafficking (240) properties from their constituent monomers. 
Valsartan is an AT1R antagonist developed clinically for the treatment of hypertension and 
congestive heart failure. It has been found that it reduces the risk of death after myocardial 
infarction. Barki-Harrington et al (231) showed the existence of direct cross-talk between AT1R 
and β-AR at the receptor level in human embryonic kidney (HEK) cells, mouse cardiomyocytes, 
and COS-7 cell lines. They found that a single receptor antagonist blocks downstream signaling 
of both AT1R and β-AR simultaneously. In particular, AT1R antagonist valsartan not only 
attenuated the activation of its corresponding receptor AT1R but also inhibited β2-AR activity and 
isoproterenol-mediated (ISO, β-AR agonist) generation of the second messenger cAMP. Similarly, 
the non-selective β-blocker propranolol not only blocked the activation of β2-AR via epinephrine 
but also inhibited the AT1R-mediated contractile response. In addition, the ability of the antagonist 
 50 
 
to inhibit receptor signaling was primarily dependent on the expression levels of both receptors. 
Specifically, they showed that valsartan transinhibited β-ARs by functionally uncoupling β-AR 
from its associated Gs protein and interrupted its downstream signaling pathway. Further, their 
findings from differential epitope tagging and selective coimmunoprecipitation suggested that β2-
AR and AT1R were assembled as oligomers on the plasma membrane (Figure 3.1). Thus, the 
trans-inhibition effect most likely worked on the β2-AR and AT1R constitutive complex formed on 
the cell membrane. However, it is not known if this cross-talk between β-AR and AT1R is active 
in RBCs. 
In this study, we investigated the influence of valsartan on the cAMP-PKA pathway by measuring 
the surface expression of active ICAM-4 receptors on human WT-, SCT-, and SS-RBCs. We 
employed an atomic force microscopy (AFM) technique called single molecule force spectroscopy 
(SMFS) (172) which can detect single functional receptors on RBCs as well as measure the 
unbinding force between a receptor and its corresponding ligand (192-195, 197, 198, 223).  We 
demonstrated that pretreatment of RBCs with valsartan significantly hindered the activation of 
ICAM-4 receptors induced by epinephrine. The findings of this work suggest that administration 
of valsartan offers a possible way to mitigate vaso-occlusive episodes in SCD.  
 
3.2. Materials and methods 
Human subjects, blood collection and preparation 
This study was approved by the Institutional Review Boards of the University of Connecticut-
Storrs and UCONN-Health. All subjects were at least 7 years old and were ineligible to participate 
if they were pregnant, breastfeeding, or within 3 months postpartum; used anti-lipid therapy within 
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the previous week; were taking an investigational drug; or received a blood transfusion within the 
previous 3 months. Additionally, homozygous SCD (SS) patients were only eligible to participate 
if they were at steady state. Steady state was defined as having not received a parenteral opioid 
in the previous 4 weeks, no pain greater than the usual daily level for 4 weeks, and no increase 
in usual non-parenteral opioid medication in the previous 4 weeks. Hydroxyurea (HU) treatment 
was an exclusion criterion because HU is known to inhibit BCAM/Lu adhesion to laminin (172, 
199) and we inferred that HU might act in a similar way inhibiting activation of ICAM-4. Subject 
demographic and clinical characteristics are provided in Table 3.1.  
 
Table 3.1. Subject demographic and clinical characteristics 
 WT SCT SS 
Subject numbers 5 3 6 
Age, mean, SD 42 (14) 34 (5) 27 (5) 
Gender, n, %    female 3 (60) 
male 2 (40) 
female 3 (100) male 5 (83) 
female 1 (17) 
Race, n, % 
    
African- 
American 4 (80) 
White 1 (20) 
 
African- 
American 2 (67) 
Latino 1 (33) 
African- 
American 6 (100) 
Hemoglobin, g/dL, 
   mean, SD 
 
14 (1) 
 
13 (1) 
 
9 (1) 
Leukocyte count, 
   K/μL, mean, SD 
 
7 (2) 
 
6 (1) 
 
12 (2) 
Platelet, K/μL, 
   mean, SD 
 
222 (37) 
 
228 (29) 
 
430 (156) 
Neutrophil, %, 
   mean, SD 
 
47 (15) 
 
58 (10) 
 
58 (10) 
Reticulocytes, %, 
mean, SD 
 
N/A  
 
N/A 
 
13 (4) 
LDH, U/L,  
mean, SD 
 
N/A 
 
N/A 
 
497 (82) 
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Blood samples of eligible subjects were collected into heparinized tubes. Whole blood was 
centrifuged at 500 ×g for 5 min at 4℃ to isolate the RBCs. The plasma and buffy coat were 
removed. The remaining RBCs were washed three times with Alsever’s solution and stored at 4℃ 
for up to 7 days. During experiments, RBCs were seeded in a glass bottom petri dish coated with 
1 mg/mL poly-L-lysine solution (Sigma-Aldrich, St. Louis, MO). At this concentration, the RBCs 
were immobilized while maintaining their original biconcave shape. All experiments were 
performed under normoxic conditions. The reason is that hypoxia and the consequent changes 
in the viscoelastic properties of SS-RBCs may play a role in the events of RBC adhesion and 
would add an unwanted level of complexity to this work whose focus is the β-AR and AT1R cross-
regulation. In our experiments, we chose to test only RBCs that had the characteristic biconcave 
shape to avoid reticulocytes, which generally have irregular shapes in our samples as tested in 
our previous work (223). 
 
Reagents 
Human integrin αvβ3 protein (100 μg/mL, diluted in PBS) was purchased from Millipore (Billerica, 
MA). Alsever’s solution, epinephrine (16.39 nM, reconstituted in Alsever’s solution), valsartan (2 
μg/mL, reconstituted in DMSO), and bovine serum albumin (BSA; 100 μg/mL, reconstituted in 
PBS) were purchased from Sigma-Aldrich (St. Louis, MO).  RBCs were treated with the reagents 
at 37℃ for 30 min. We note that the peak value of plasma valsartan concentration after a single 
80 -160 milligrams oral dose administration of clinical valsartan tablet was approximately 2 μg/mL 
(241, 242). Also, the maximum daily valsartan dose for adults is 320 mg, and the peak plasma 
concentration was measured to be 5.5 μg/mL (243). Testing the effects of valsartan at different 
concentrations on SS-RBC ICAM-4 expression using SMFS, we found that there was no 
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significant difference between the effect of valsartan at 1, 2, and 10 μg/mL (the corresponding 
active ICAM-4 densities were 11.46 ± 1.18%, 8.77 ± 1.58%, and 7.32 ± 1.32%). Based on these 
results, which cover the entire spectrum of clinical valsartan dose administration, we decided to 
use 2 μg/mL in our experiment, which is close to the peak plasma concentration resulted from the 
recommended starting dose. 
 
AFM probe functionalization 
Silicon nitride AFM probes were purchased from Bruker Nano Inc. (Camarillo, CA). The tip height 
was 2.5 - 8 μm and the nominal tip radius was 20 nm. The nominal spring constant of the applied 
cantilever is 30 pN/nm. The actual spring constant under the experimental condition (in Alsever’s 
solution at 37℃) was computed using a thermal noise collecting method (202, 203). The 
cantilevers were first soaked in 2% v/v 3-aminopropyltriethoxysilane (APTES) in acetone (Sigma-
Aldrich, St. Louis, MO) for 10 min, then rinsed with deionized (DI) water. Cantilevers were treated 
with 0.5% v/v glutaraldehyde (solution in DI water) for 30 min to adhere the glutaraldehyde 
molecule linker, then rinsed again with DI water and incubated in 100 μg/mL αvβ3 solution to 
attach the ligand. After 30 min, the cantilevers were rinsed again with DI water and immersed in 
100 μg/mL BSA for 1 min to block the residual aldehyde groups. Cantilevers were stored in PBS 
at 4℃ and used within three days. 
 
 
 
 54 
 
AFM setup 
All experiments were performed using the MFP-3D-BIO AFM (Asylum Research, Santa Barbara, 
CA), which was mounted on an inverted microscope (Zeiss Axiovert A1, Oberkochen, Germany). 
The microscope gave a clear image of RBCs, which were seeded in a transparent glass bottom 
petri dish allowing us to choose RBCs that were less than 10 μm in diameter and maintained a 
distinct circular biconcave shape. For each experimental condition, 5 RBCs were tested from each 
subject. A schematic of a functionalized AFM probe scanning the membrane of a RBC is shown 
in Figure 3.2 A. 
 
Figure 3.2. Schematic of a SMFS experiment along with a representative force-
displacement measurement and the corresponding histogram. (A) AFM probing illustration. 
The yellow colored element represents the glutaraldehyde linker and the ligand αvβ3 protein 
molecule attached to the cantilever tip. (B) Representative force-displacement curve. The red 
curve denotes approach and the blue curve denotes retraction. (C) Frequency distributions of 
unbinding forces between ICAM-4 and αvβ3 in WT-, SCT-, and SS-RBCs. 
 
Force-distance curves were recorded at 32×32 points as the cantilever scanned over a 1μm2 area 
of the RBC surface. Each curve contained a full approach and retraction trace (as shown in Figure 
3.2 B). We have shown that 1 μm2 scanning area for SMFS experiments on RBCs gives a 
representative result for the specific tested RBC (167). When unbinding events occurred between 
the αvβ3-functionalized cantilever and ICAM-4 receptors expressed on the RBC membrane, an 
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unbinding force was displayed as the cantilever was retracted from the cell surface (172, 223). 
The unbinding force was measured as the magnitude of the abrupt drop to zero of the retraction 
force-displacement curve (Figure 3.2 B). All data were processed using our in-house developed 
code named FRAME (Force Review Automation Environment) (204). 
The cantilever approach/retraction speed was held constant at 800 nm/s, which corresponds to a 
nominal loading rate of 24,000 pN/s. At this speed, the force measurements were not significantly 
affected by hydrodynamic drag (Figure 3.2 B) as it is clear from the overlapping between the 
approach and retraction curves before and after contact with the RBC membrane (205). We only 
considered the unbinding events for which the effective spring constants (Keff) were less than 10 
pN/nm which, in combination with the cantilever moving speed, ensures that the influence of Keff 
on the magnitude of the unbinding force for the specific loading rate is not significant for SMFS 
experiments (206). The effective spring constants were calculated from the slopes of the curves 
adjacent to the unbinding force drops (207, 208). A specific threshold was set to control the 
indentation depth and to apply the same nominal maximum force to each RBC. The probe traveled 
a distance of ~200 nm, which corresponded to a contact time between the probe and the RBC 
membrane of ~1/4 s before retraction. 
To illustrate the population of the active ICAM-4 receptors on the RBC surface, the collective 
frequencies were showed in box-and-whisker plots. Collective frequency (CF, %) was defined as 
the percentage of all unbinding events with respect to the total number of measurements 
(32×32=1024 for each cell). The CF revealed the percentage of active ICAM-4 receptors that 
were able to bind to αvβ3. This approach allowed the observation of the modulation of the CF of 
activated ICAM-4 receptors in the presence of valsartan and the other biochemical reagents. 
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Statistical methods 
The unbinding forces between αvβ3 ligands and ICAM-4 receptors are reported using frequency 
(%) distribution which states the percentage of events whose corresponding unbinding forces 
were within each bin's width (Figure 3.2 C). The CF results are reported as mean ± standard error 
(SE) and illustrated by box-and-whisker plots (GraphPad Prism, GraphPad Software, Inc., La Jolla, 
CA). Significance was determined using one-way analysis of variance (ANOVA). The results were 
considered significant if p<0.05.  
 
3.3. Results and discussion 
First, we verified previous findings that epinephrine stimulates the activation of ICAM-4 receptors 
on WT-, SCT- and SS-RBCs (173, 223). Epinephrine, as a catecholamine, acts on β-ARs and 
stimulates the cAMP- PKA-dependent signaling pathway. The purpose of these experiments was 
to exclude the variance due to different blood samples and only compare the variation of active 
ICAM-4 receptors caused by the different reagents that we used. We employed the SMFS assay 
to scan a 1 μm × 1 μm membrane areas of individual RBCs with an AFM cantilever functionalized 
with αvβ3 to detect variation of active ICAM-4 receptors and measure the unbinding forces 
between active ICAM-4 and αvβ3 under different experimental conditions. 
Treatment with epinephrine caused a significant increase in the CF of active ICAM-4 receptors 
on the surface membrane of WT-RBCs from 8.98 ± 1.20% at baseline to 17.00 ± 1.89% (p=0.0003; 
Figure 3.3 A, Table 3.2). The CF of active ICAM-4 receptors of SCT-RBCs was measured to be 
5.58 ± 0.76% at baseline, which is similar to the CF obtained for WT-RBCs (p=0.4696). Treatment 
of SCT-RBCs with epinephrine significantly increased the CF of active ICAM-4 receptors to 17.11 
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± 1.50% (p<0.0001; Figure 3.3 B, Table 3.2). The CF of active ICAM-4 adhesion was 11.68 ± 
1.68% for SS-RBCs at baseline, which is higher than that measured for WT- and SCT-RBCs, but 
not significantly (p=0.9999, 0.1768). Similar to the observations made in WT- and SCT-RBCs, 
SS-RBCs treated with epinephrine demonstrated significantly higher CF of active ICAM-4 
receptors 20.58 ± 2.76% (p=0.0019; Figure 3.3 C, Table 3.2) compared to baseline.  
Table 3.2. Collective frequencies of active ICAM-4 receptors for WT-, SCT- and SS-RBCs 
 
 
Figure 3.3. Box-and-whisker plots of the CF of active ICAM-4 receptors on (A) WT-RBCs, 
(B) SCT-RBCs, (C) SS-RBCs. Data are shown as the median with minimum and maximum 
whiskers, and the mean is denoted as a color dot. Significance between conditions is denoted 
as * such that p<0.05. The n on the x-axis indicates the total number of mature RBCs tested in 
each group: WT-RBC: 5 subjects; SCT-RBC: 3 subjects; SS-RBC: 6 subjects. 
 
Valsartan suppresses the activation of ICAM-4 receptors induced by epinephrine 
 Collective frequency (mean ± SE, %) 
WT SCT SS 
Test condition    
Baseline 8.98 ± 1.20 5.58 ± 0.76 11.68 ± 1.68 
+epinephrine 17.00 ± 1.89 17.11 ± 1.50 20.58 ± 2.76 
+valsartan 5.20 ± 0.57 3.13 ± 0.22 6.41 ± 0.91 
+valsartan +epinephrine 10.41 ± 1.35 6.87 ± 0.91 10.07 ± 1.02 
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Valsartan is an AT1R blocker and a common clinical drug for treatment of hypertension and heart 
failure. In addition, it has been demonstrated that in cardiomyocytes, HEK 239 and COS-7 cells 
valsartan can simultaneously block downstream signaling of both AT1R and β-AR by affecting 
AT1R and β-AR heterodimers by diminishing the coupling between a β-AR and its corresponding 
Gs protein (231). In this work, we investigated if treatment of RBCs with valsartan would affect 
the CF of active ICAM-4 receptors expressed on the surface membrane of the RBCs. We found 
that valsartan-treated WT-RBCs exhibited similar CF of active ICAM-4 to untreated WT-RBCs 
(5.20 ± 0.57% vs. 8.98 ± 1.20%, p=0.2178; Figure 3.3 A; Table 3.2), but significantly lower CF of 
active ICAM-4 than epinephrine-treated WT-RBCs (5.20 ± 0.57% vs. 17.00 ± 1.89%, p<0.0001; 
Figure 3.3 A; Table 3.2). Then, we investigated if valsartan affects epinephrine stimulation of 
active ICAM-4 adhesion receptors. To this end, we sequentially incubated WT-RBCs with first 
valsartan and then epinephrine and compared their combined effect on the CF of ICAM-4 
receptors with that of epinephrine exposure alone. We demonstrated that pre-treatment with 
valsartan resulted in a significant decrease in the expected epinephrine-induced activation of 
ICAM-4 adhesion receptors (10.41 ± 1.35% vs. 17.00 ± 1.89%, p=0.0045, Figure 3.3 A; Table 
3.2). 
Similar experiments were performed on SCT-RBCs. As with WT-RBCs, SCT-RBCs showed no 
distinct change in the CF of active ICAM-4 when RBCs treated only with valsartan (3.13 ± 0.22% 
vs. 5.58 ± 0.76%, p=0.2497, Figure 3.3 B; Table 3.2). However, when SCT-RBCs were treated 
with valsartan prior to their exposure to epinephrine, the CF of ICAM-4 receptors was significantly 
lower compared to treatment with only epinephrine (6.87 ± 0.91% vs. 17.11 ± 1.50%, p<0.0001, 
Figure 3.3 B; Table 3.2). 
The same experiments were then performed on SS-RBCs. Similarly to WT-RBCs and SCT-RBCs, 
SS-RBCs exhibited a comparable level of active ICAM-4 to baseline SS-RBCs with valsartan 
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treatment alone (6.41 ± 0.91% vs. 11.68 ± 1.68%, p=0.1195, Figure 3.3 C; Table 3.2), but showed 
a significant decrease with valsartan prior to epinephrine treatment compared to treatment with 
only epinephrine (10.07 ± 1.02% vs. 20.58 ± 2.76%, p=0.0004, Figure 3.3 C; Table 3.2). 
At baseline, WT-, SCT- and SS-RBCs demonstrated similar unbinding forces between the αvβ3 
ligand and ICAM-4 (Figure 3.3.2 C). In addition, neither epinephrine nor valsartan altered the 
unbinding force level between the αvβ3 ligand and ICAM-4 receptor, suggesting the reagents 
affect only the activation of ICAM-4 receptors and not the strength of their interactions with αvβ3. 
AT1R blockade significantly decreased the epinephrine-induced increase in the CF of active 
ICAM-4 adhesion receptors in WT-, SCT- and SS-RBCs. These findings suggest that valsartan 
efficiently suppressed the effect of epinephrine on the activation of ICAM-4 receptors in WT-, 
SCT-, and SS-RBCs. As postulated in previous research (231), β-AR and AT1R may form a 
constitutive complex on the RBC membrane. Administration of valsartan could act on the complex, 
not only blocking the action of AT1R but also uncoupling the β-AR and its cognate Gs protein. In 
this case, epinephrine could no longer effectively stimulate β-AR and the following cAMP-PKA-
dependent pathway through Gsα dissociation. The nature of the uncoupling effect may involve a 
conformational change on β-AR making it no longer favorable to bind to Gs protein which is 
currently under investigation (231, 244). 
 
3.4. Conclusions 
In this study, we explored the effect of valsartan on the activation of ICAM-4 receptors on WT-, 
SCT- and SS-RBCs. We observed that epinephrine significantly increased the surface percentage 
of active ICAM-4 receptors on WT-, SCT- and SS-RBCs. Importantly, we showed that although 
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exposure to valsartan alone did not have a significant effect on basal level adhesion, pre-
treatment of RBCs with valsartan prior to epinephrine stimulation resulted in a significant decrease 
in the percentage of active ICAM-4 receptors compared to treatment with only epinephrine. This 
may have major clinical implications as our data suggest that valsartan can modulate SS-RBCs 
adhesion, which is a known contributor to vaso-occlusion. Our findings suggest that administration 
of valsartan could mitigate the vaso-occlusive consequences of SCD and may open new avenues 
for the development of novel therapeutic targets. 
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Chapter 4. Influence of Clinical Chemotherapeutic Agents on the Activation of 
RBC ICAM-4 Adhesion Receptors Varies Due to Race and SCT Carrying Status 
4.1. Introduction 
African-Americans have worse cancer survival prognosis compared to whites (245, 246), 
particularly among female breast cancer patients. This cannot be fully explained by either socio-
economic or tumor marker expression differences (246-248). Although mortality from breast 
cancer has been falling for white women in recent years across the United States, the death rate 
for African-Americans has declined more slowly resulting in a growing disparity (246). It has been 
long-recognized that African-American women with breast cancer have lower survival probability 
compared to women of European ancestry in nearly all states in the United States (249, 250). 
This disparity is particularly perplexing given that the incidence of breast cancer has been 
consistently lower in African-Americans. African-Americans also experience higher rates of 
adverse events during systemically administered cancer chemotherapy (251). A survival disparity 
was observed in a pooled analysis of clinical trial conducted by the southwest oncology group 
(SWOG), when patients received uniform treatment, suggesting that inherited host factors might 
contribute to disparate cancer-treatment outcomes (252). An unstudied genetic trait in cancer 
outcomes are hemoglobinopathies, particularly sickle cell trait (SCT) which is estimated to occur 
in 8 -10% of African-Americans but in only ~0.001% of white Americans of European ancestry 
(253).  
People with SCT carry both normal and abnormal version of the Hemoglobin gene (i.e., HbAS), 
which is responsible for expression of the β-chain of hemoglobin. There have been reports 
describing chemotherapy-induced intravascular sickling including those known as SCT carriers 
and have been asymptomatic previously (175, 254-256). Subsequent vaso-occlusion (overt or 
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sub-clinical) may give rise to symptoms such as pain and nausea, or clinical signs such as 
unexplained anemia and renal insufficiency. These signs and symptoms may lead to treatment 
delays, dose-reductions and in some cases, cessation of therapy, all of which can impact efficacy 
and, most importantly, survival. Sickling crises were also reported in patients with SCT undergoing 
chemotherapy for cervical cancer (257).  
Current research suggests that vaso-occlusion in SCD are, in part, due to complex intravascular 
hetero-cellular interactions between RBCs, leukocytes and endothelial cells (ECs) that lead to 
microvascular obstruction, distal ischemia and resultant organ damage (175, 254, 258-260). 
Several receptor-ligand interactions have been shown to be critical to SCD RBC-EC adhesion 
including BCAM/Lu – laminin (128), and ICAM-4 – αvβ3 (261).  Our group has focused on defining 
the signaling pathways associated with enhanced RBC adhesion in SCD (172, 205, 223).  If we 
could show a correlation between SCT and the genesis of vaso-occlusive complications in cancer 
treatment, we may expand current knowledge of potentially modifiable biologic differences 
between whites and blacks narrowing the gap in cancer treatment outcomes. 
The identification of biological reasons for cancer survival disparities between blacks and whites 
is in critical need. To our knowledge, we are the first to explore enhanced RBC adhesion as a 
potential etiology for disparate survival among black women with breast cancer. By applying 
single molecule-AFM technique, we were able to measure the adhesion between ICAM-4 
receptors on RBC with endothelial αvβ3 integrins attached to the AFM cantilever tip. This may set 
the basis for the future clinical procedure, running SCT carrier screening prior to chemotherapy 
treatment in order to optimize therapeutic approaches and potentially improve patient outcomes. 
We measured the number of active ICAM-4 adhesion receptors on RBCs from three groups of 
participants: white female with wild-type hemoglobin (WFWT), black female with wild-type 
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hemoglobin (BFWT), and black female sickle cell trait (BFSCT) with and without the administration 
of two chemotherapeutic agents, cyclophosphamide (CYP) and daunorubicin (DNR). We found 
that both drugs did not affect the ICAM-4 expression on WFWT-RBCs. CYP increased the ICAM-
4 expression on BFWT-RBCs. DNR increased the ICAM-4 expression on BFSCT-RBCs. The 
findings suggest race and SCT carrying status might be crucial factors in choosing chemotherapy 
regimens for different patients.  
 
4.2. Materials and methods 
Human subjects, blood collection and preparation 
This study was approved by the Institutional Review Boards of the University of Connecticut-
Storrs and UCONN-Health. The target population included healthy female volunteers with and 
without SCT.  Healthy volunteers (with or without known SCT) were eligible if they are at least 18 
years old and do not self-identify as having SCD and were excluded if they are pregnant, breast-
feeding, within 3 months post-partum, have received a blood transfusion within the preceding 3 
months, are taking prescription medication or an investigational drug, or have had surgery within 
the previous 6 weeks. We enrolled three groups of healthy study participants: black females with 
wild-type hemoglobin (BFWT), white females with wild-type hemoglobin (WFWT), and black 
female sickle cell trait carriers (BFSCT). Subject demographic and clinical characteristics are 
provided in Table 4.1. 
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Table 4.1. Subject demographic and clinical characteristics 
 BFWT WFWT BFSCT 
Subject numbers 3 3 4 
Age, mean, SD 42 (6) 52 (14) 34 (5) 
Gender, n, %    female 3 (100) female 3 (100) female 4 (100) 
Race, n, %   African- 
American 3 (100) 
 
White 3 (100) 
African- 
American 4 (100) 
Hemoglobin, g/dL, 
   mean, SD 
 
13 (1) 
 
14 (1) 
 
13 (1) 
Leukocyte count, 
   K/μL, mean, SD 
 
7(2) 
 
4 (0) 
 
6 (1) 
Platelet, K/μL, 
   mean, SD 
 
246 (63) 
 
245 (40) 
 
228 (29) 
Neutrophil, %, 
   mean, SD 
 
53 (17) 
 
43 (4) 
 
58 (10) 
 
Blood samples of eligible subjects were collected into heparinized tubes after obtaining informed 
consent. Whole blood was centrifuged at 500 ×g for 5 min at 4℃ to isolate the RBCs. The plasma 
and buffy coat were then removed. The remaining RBCs were washed three times with Alsever’s 
solution and stored at 4℃ and used within 7 days. To immobilize the RBCs in the meantime to 
maintain their biconcave shape, they were seeded in a glass bottom petri dish pretreated with 1 
mg/mL poly-L-lysine solution (Sigma-Aldrich, St. Louis, MO) for 15 min. All measurements were 
obtained under normoxic conditions because hypoxia may introduce a syndrome resembling 
sickle cell disease (SCD) in sickle cell trait (SCT)-RBCs with sickling and enhanced adhesiveness. 
 
Ligand and drugs 
Human integrin αvβ3 protein (100 mg/mL, diluted with PBS) was obtained from Millipore (Billerica, 
MA). Alsever’s solution, Cyclophosphamide (CYP, 80.335 μM, reconstituted in DMSO), 
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Daunorubicin (DNR; 57.988 μM, reconstituted in DMSO), and bovine serum albumin (BSA; 100 
mg/mL, reconstituted in PBS) were purchased from Sigma-Aldrich (St. Louis, MO). RBCs were 
treated with the above-mentioned drugs at 37 ℃ for 30 min. 
 
AFM cantilever probe functionalization 
Soft silicon nitride cantilevers with silicon nitride tips were purchased from Bruker Nano (Camarillo, 
CA). The tip height was between 2.5 and 8 mm and the nominal tip radius was 20 nm. The nominal 
spring constant of the applied cantilever was 30 pN/nm. The actual spring constant under the 
experimental condition (in Alsever’s solution at 37 ℃) was calculated via a thermal-noise-based 
method. Silicon nitride probes were first amino-functionalized with 2% v/v 3-
aminopropyltriethoxysilane in acetone (Sigma-Aldrich) for 10 min and then rinsed with deionized 
(DI) water. The probes were soaked in 0.5% v/v glutaraldehyde (solution in DI water) for 30 min, 
rinsed again with DI water, and incubated in a 100 mg/mL αvβ3 solution. After 30 min, the probes 
were rinsed with DI water and immersed in 100 mg/mL of BSA for 1 min to block the remaining 
aldehyde groups. The probes were stored in PBS at 4℃ and used within 3 days. 
 
Statistical analysis 
The unbinding forces between αvβ3 ligands and intercellular adhesion molecule-4 (ICAM-4) 
receptors are reported using the frequency (%) distribution, which states the percentage of events 
whose unbinding forces are within each bin’s width. We then compared the median values of the 
forces measured in experiments without and with treatment with different drugs. The zero force 
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points are not shown because they would obscure the plots since their population is much larger 
than the population of unbinding events. The collective frequency (CF, %) is related to the 
population of active ICAM-4 receptors and is defined as the percentage of all unbinding events 
divided by the total number of measurements, which is 32 × 32 =1024 for each cell multiplied by 
the number of tested cells for each blood sample. The CF results are reported as the mean ± 
standard error (SE) and illustrated by box-and-whisker plots (GraphPad Prism, GraphPad 
Software, San Diego, CA). Statistical significance was determined by one-way analysis of 
variance (ANOVA) and the Tukey-Kramer post hoc test. The results are considered significant if 
p < 0.05. 
 
4.3. Results and discussion 
We first measured the CF of active ICAM-4 receptors and the unbinding force between αvβ3 and 
ICAM-4 on black female normal RBCs (BFWT-RBCs) with and without CYP and DNR treatment. 
The CF of active ICAM-4 receptors was measured to be 6.82 ± 1.30% for BFWT-RBCs at baseline 
(without treatment). Treatment of BFWT-RBCs with CYP significantly increased the CF of active 
ICAM-4 receptors to 15.72 ± 1.91% (p=0.0001; Figure 4.1, Table 4.2). Treatment of BFWT-RBCs 
with DNR held the CF of active ICAM-4 receptors at similar level 7.79 ± 0.78% (p=0.8794; Figure 
4.1, Table 4.2) as the baseline value. There was also a significant difference in the number of 
active ICAM-4 adhesion receptors between CYP treated and DNR treated BFWT-RBCs 
(p=0.0008, Figure 4.1). 
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Figure 4.1.  BFWT-RBC ICAM-4 expression with and without CYP and DNR treatments. 
(A) Frequency distributions of unbinding forces between ICAM-4 and αvβ3 in BFWT-RBCs. (B) 
Box-and-whisker plot of the CF of active ICAM-4 receptors on BFWT-RBCs. Data are shown 
as the median with minimum and maximum whiskers, and the mean is denoted as a color dot. 
Significance between conditions is denoted as * such that p<0.001. The ‘n’ on the x-axis 
indicates the total number of RBCs analyzed in each condition, obtained from 3 subjects. 
 
Table 4.2. Unbinding forces between ICAM-4 and αvβ3 and collective frequencies of active ICAM-
4 receptors for BFWT-, WFWT- and BFSCT-RBCs 
 
Next, we measured the CF of active ICAM-4 receptors and the unbinding force between αvβ3 
and ICAM-4 on RBCs from white females with wild-type hemoglobin (WFWT-RBCs) with and 
without CYP and DNR treatment. The CF of active ICAM-4 receptors was measured to be 9.54 ± 
1.31% for WFWT-RBCs at baseline. Treatment of WFWT-RBCs with CYP and DNR both held the 
 Unbinding force (median, pN) Collective frequency (mean ± SE, %) 
BFWT WFWT BFSCT BFWT WFWT BFSCT 
Test 
condition 
  
  
  
Baseline 25.90 26.05 26.99 6.82 ± 1.30 9.54 ± 1.31 4.88 ± 0.87 
+CYP 30.99 26.47 25.71 15.72 ± 1.91 7.51 ± 1.48 6.59 ± 1.05 
+DNR 26.31 28.27 34.15 7.79 ± 0.78 7.47 ± 1.07 13.13 ± 2.30 
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CF of active ICAM-4 receptors at the similar level as the untreated WFWT-RBCs (CYP: 7.51 ± 
1.48%, p=0.514; DNR: 7.47 ± 1.07%, p=0.5012; Figure 4.2, Table 4.2). Also, there was no 
significant difference in the number of active ICAM-4 adhesion receptors between CYP treated 
and DNR treated WFWT-RBCs (p=0.9998, Figure 4.2).  
 
Figure 4.2.  WFWT-RBC ICAM-4 expression with and without CYP and DNR treatments. 
(A) Frequency distributions of unbinding forces between ICAM-4 and αvβ3 in WFWT-RBCs. 
(B) Box-and-whisker plot of the CF of active ICAM-4 receptors on WFWT-RBCs. Data are 
shown as the median with minimum and maximum whiskers, and the mean is denoted as a 
color dot. The ‘n’ on the x-axis indicates the total number of RBCs analyzed in each condition, 
obtained from 3 subjects. 
 
Finally, we measured the CF of active ICAM-4 receptors and the unbinding force between αvβ3 
and ICAM-4 on RBCs from black females with sickle cell trait (BFSCT-RBCs) with and without 
CYP and DNR treatment. The CF of active ICAM-4 receptors was measured to be 4.88 ± 0.87% 
for BFSCT-RBCs at baseline. Treatment of BFSCT-RBCs with CYP held the CF of active ICAM-
4 receptors at similar level 6.59 ± 1.05% (p=0.7329; Figure 4.3, Table 4.2) as the baseline value. 
Treatment of BFSCT-RBCs with DNR significantly increased the CF of active ICAM-4 receptors 
to 13.13 ± 2.30% (p=0.00014; Figure 4.3, Table 4.2) compared to the baseline. In addition, there 
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was a significant difference in the number of active ICAM-4 adhesion receptors between CYP 
treated and DNR treated BFSCT-RBCs (p=0.013, Figure 4.3). 
 
Figure 4.3.  BFSCT-RBC ICAM-4 expression with and without CYP and DNR treatments. 
(A) Frequency distributions of unbinding forces between ICAM-4 and αvβ3 in BFSCT-RBCs. 
(B) Box-and-whisker plot of the CF of active ICAM-4 receptors on BFSCT-RBCs. Data are 
shown as the median with minimum and maximum whiskers, and the mean is denoted as a 
color dot. Significance between conditions is denoted as * such that p<0.05. The ‘n’ on the x-
axis indicates the total number of RBCs analyzed in each condition, obtained from 4 subjects. 
 
In summary, our experiments showed that CYP significantly increased the activation of ICAM-4 
receptors on BFWT-RBCs but not on WFWT-RBCs and BFSCT-RBCs; DNR significantly 
increased the activation of ICAM-4 receptors on BFSCT-RBCs but not on BFWT-RBCs and 
WFWT-RBCs. The findings indicated that the effect of chemotherapeutic agents on RBC ICAM-
4 expression varied due to race and SCT carrying status, suggesting they might be critical factors 
in choosing chemotherapy regimens for different patients. SCT has been thought to have no 
impact on survival in general.  Hence, most adults with SCT and their care-providers, are not 
aware of their SCT carrier status (262). Genetic screening for SCD/SCT status has only been 
introduced as part of routine newborn screening nationally in the past two decades. However, 
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there have been reports of patients with SCT undergoing chemotherapy developing sickle cell 
crisis (122). In terms of the impact on survival, there are reports that African-American women 
with breast cancer have higher rates of self-withdrawal from treatment even in national 
cooperative trials, this might reflect, in part, some degree of adverse consequences related to 
SCT interaction with chemotherapy. The finding of SCT being a clinically significant problem in 
the context of chemotherapeutic treatment may lead to novel approaches to reverse disparities in 
cancer treatment outcomes among African-Americans. 
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Chapter 5. Further Approaches to Understand RBC Biophysics 
5.1. AFM-based microrheology measures RBC viscoelastic properties 
RBCs experience large deformation during microcirculation given that the diameter of the smallest 
capillaries is only one-third of a normal RBC’s diameter (263). Changes in cell deformability, as 
occur in SCD, have an essential role in microcirculatory dysfunction. To better understand how 
mechanical stresses and deformations regulate cellular functions requires a detailed knowledge 
of the mechanical properties of cells. Normal RBC deformability has been measured in terms of 
the shear, bending, and area expansion moduli of the cell membrane using various techniques, 
including micropipette aspiration, optical tweezers, and high-frequency electrical deformation 
tests, which apply quasi-static loads and can achieve large deformations (264-270). Further, the 
viscoelastic properties of the normal RBC in response to time-dependent loads were studied 
through optical magnetic twisting cytometry, which applies a torque to a ferrimagnetic micro-bead 
tightly bound to the cell surface (271). However, the bead binding positions were quite random 
and hardly repeatable. In comparison, AFM provides a more efficient way to generate time-
dependent loadings, record RBC responses, and measure RBC viscoelasticity by calculating the 
absolution value of the complex modulus, 𝐺∗(𝜔). The tip at the end of a flexible cantilever is able 
to locally indent the cell membrane with a precise control of the loading rate. 𝐺∗(𝜔) is defined as 
he complex ratio in the frequency domain between the applied stress and the resulting strain 
(272). The real and imaginary parts of 𝐺∗(𝜔) account for the storage modulus (elastic modulus) 
𝐺′ and the loss modulus (frictional modulus) 𝐺″ respectively. 
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When cells are exposed to sinusoidal oscillating, the strain is neither exactly in phase with the 
stress (as it would be for a perfect elastic solid) nor 90° out of phase (as it would be for a perfect 
viscous liquid) but is somewhere in between. This means cells are viscoelastic, exhibiting both 
solid- and liquid-like characteristics. Cells store and dissipate mechanical energy and response 
to mechanical stimuli depending on the rate at which the stimuli are applied (161, 271, 273). 
Method described here (Figure 5.1, 5.2) may be applicable to characterize and connect the 
mechanical and biological properties of the RBC in health and disease. It measured complex 
modulus over various loading frequencies generated by an AFM with the corrections of system 
lag and hydrodynamic viscous drag. The triangle cantilever with a tip was used to locally indent a 
cell. The tip height was between 2.5 and 8 μm and the nominal tip radius was 20 nm. The nominal 
resonant frequency of the cantilever was 15 kHz. The nominal spring constant of the applied 
cantilever was 30 pN/nm. The actual spring constant (𝑘) under the experimental condition (in 
Alsever’s solution at 37℃) was calculated by a thermal noise based method (202, 203). The 
cantilever oscillated around the indentation depth 𝛿0 (~200nm, 10% of the thickness of an RBC) 
with a 5 nm amplitude at different frequencies: 5, 10, 25, 50, 75, 100, 120, 150, 200 Hz. There 
were 12 cycles of sinusoidal oscillation at each frequency and 0.5s of resting time between 
frequencies. 
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Figure 5.1. Schematic illustration of a cantilever tip oscillates in contact with a cell. 
Oscillation was controlled around the indentation depth δ0  with an amplitude δ𝜔  at the 
frequency ω (273).  
 
 
Figure 5.2. AFM generates time-dependent loadings. Time-dependent loading function (top) 
and the corresponding force-time curve (bottom) obtained from an AFM tip indenting a normal 
RBC. When the cantilever gets into contact with the cell, the force increases rapidly until the 
given trigger point is reached. During dwell in contact, the cantilever is excited to sinusoidal 
oscillations with frequencies 5, 10, 25, 50, 75, 100, 120, 150, 200 Hz with the amplitude of 5 
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nm, 12 cycles of each frequency and 0.5s of resting time between frequencies. Afterward, the 
cantilever is retracted. 
 
5.1.1 Correction of phase lag between excitation of the cantilever and the force response 
First, the system lag (𝜑𝑙𝑎𝑔) between excitation of the cantilever (Z position) and the force response 
in a viscous environment was tested for every frequency in each measurement. Zsensor-time and 
force-time curves were recorded when ramping the Z position (displacement) with 5 nm amplitude 
sinusoidal oscillations at different frequencies (5-200 Hz) and with tip-substrate in contact (Figure 
5.3). Since the substrate was a hard glass surface, the deviation from 0° phase shift was 
compensated. 
 
Figure 5.3. Zsensor-time and force-time curves when ramping the AFM tip on a hard 
substrate. Time-dependent loading function (top) and the corresponding force-time curve 
(bottom) obtained from oscillating an AFM tip on a hard glass substrate. When the cantilever 
gets into contact with the substrate, the force increases rapidly until the given trigger point is 
reached. During dwell in contact, the cantilever is excited to sinusoidal oscillations with 
frequencies 5, 10, 25, 50, 75, 100, 120, 150, 200 Hz with the amplitude of 5 nm, 12 cycles of 
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each frequency and 0.5s of resting time between frequencies. Afterward, the cantilever is 
retracted. 
 
5.1.2. Correction of hydrodynamic drag force 
Force measurements with AFM in the liquid are subjected to the hydrodynamic drag force (𝐹ℎ) 
due to viscous friction of the cantilever with the liquid. The effect of hydrodynamic drag is modeled 
in Figure 5.4.  
 
Figure 5.4. A mechanical model of the cantilever tip in contact with a soft sample in 
liquid. The cantilever is represented by a 1-D oscillator with spring constant 𝑘 and effective 
mass 𝑚𝑒𝑓𝑓. The sample displacement is produced by the piezoactuator (274). 
 
When testing a sample in liquid, the force exerted on the cantilever (𝐹) has two main components: 
the force applied by the sample (𝐹𝑠) and the hydrodynamic drag force (𝐹ℎ) applied by the liquid. 
Common approaches estimate 𝐹ℎ at a certain distance above the sample and subtract its value 
from the contact force measured on the sample. However, this procedure can underestimate 𝐹ℎ 
at contact. Instead, drag forces of liquid on the cantilever can be measured in noncontact when 
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ramping the Z position (displacement, see Figure 5.5) with low-amplitude (5 nm) sinusoidal 
oscillations at different frequencies (𝜔, 5-200 Hz) and tip-substrate distances (ℎ, 0.25-4 μm). Then 
drag factor at contact can be obtained by extrapolation. 
 
Figure 5.5. Z-displacement input function for calculating the hydrodynamic drag factor. 
sectionⅠ: pull the tip away from glass substrate to a certain height (e.g. 250 nm); sectionⅡ: 
rest a short time, 0.5s; section Ⅲ: oscillate the cantilever under 5, 10, 25, 50, 75, 100, 120, 
150, 200 Hz with the amplitude of 5 nm, 12 cycles of each frequency and 0.5s of resting time 
between frequencies. 
 
The displacement of the piezo (𝑧) consists of the sample indentation (𝛿) and cantilever deflection 
(𝑑) as shown in Figure 5.5. The relative velocity between the cantilever and the surface of the 
sample is 𝑣 =
𝑑𝛿
𝑑𝑡
. The variables 𝑧  and 𝑑  can be measured directly. Then, 𝐹  and 𝛿  can be 
computed as 𝐹 = 𝑘𝑑 and 𝛿 = 𝑧 − 𝑑. The equation of motion of the cantilever is 
 𝑚𝑒𝑓𝑓
𝑑2𝑑
𝑑𝑡2
+ 𝑘𝑑 = 𝐹𝑠 + 𝐹ℎ   (5.1) 
 
Ⅱ 
Ⅰ 
Ⅲ 
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The microrheological behavior of the sample can be characterized in the frequency domain with 
a mechanical transfer function defined as 𝐻𝑠(𝜔) = 𝐹𝑠(𝜔)/𝛿(𝜔), where 𝐹𝑠(𝜔) and 𝛿(𝜔)are the 
fourier transforms of 𝐹𝑠and 𝛿, respectively, and 𝜔 is the oscillation frequency. 𝐻𝑠(𝜔) is a complex 
value for viscoelastic samples and is expected to show the same frequency dependence as the 
complex modulus. Similarly, the viscoelastic behavior of the liquid is characterized by the 
hydrodynamic drag transfer function defined as 𝐻ℎ(𝜔) = 𝐹ℎ(𝜔)/𝛿(𝜔). Transforming equation (5.1) 
to the frequency domain and dividing by 𝛿(𝜔) 
(−4𝜋2𝑚𝑒𝑓𝑓𝜔
2 + 𝑘)
𝑑(𝜔)
𝛿(𝜔)
= 𝐻𝑠(𝜔) + 𝐻ℎ(𝜔)                                                                                                 (5.2) 
Solving equation (5.2) for 𝐻𝑠(𝜔) 
𝐻𝑠(𝜔) = [1 − (
𝜔
𝜔0
)2]𝐻(𝜔) − 𝐻ℎ(𝜔)                                                                                                                (5.3) 
Where 𝜔0 is the resonant frequency of the cantilever and 𝐻(𝜔) is the global mechanical transfer 
function. At low frequencies (𝜔 ≪ 𝜔0) , equation (5.3) can be simplified as 
𝐻𝑠(𝜔) = 𝐻(𝜔) − 𝐻ℎ(𝜔)                                                                                                                              (5.4) 
In low Reynolds number conditions (Re < 1), the hydrodynamic drag force is expressed as below 
and increases proportionally with the relative velocity (𝑣). 
𝐹ℎ = 𝑏(ℎ)𝑣                                                                                                                                        (5.5) 
The corresponding drag transfer function has the form 
𝐻ℎ(𝜔) = 2𝜋𝑖𝜔𝑏(ℎ)                                                                                                                           (5.6) 
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The drag factor at contact, 𝑏(0), can be estimated by measuring 𝐻ℎ(𝜔) at different distances, 
computing 𝑏(ℎ) with equation (5.6) and extrapolating to ℎ = 0 with the scaled spherical model 
(5.7).  
𝑏(ℎ) =
6𝜋𝜂𝑎𝑒𝑓𝑓
2
ℎ+ℎ𝑒𝑓𝑓
                                                                                                                                          (5.7) 
Where 𝜂  is the liquid viscosity, 𝑎𝑒𝑓𝑓  is the effective radius of the cantilever, and ℎ𝑒𝑓𝑓  is the 
effective height of the tip. Alcaraz et al suggest that drag artifact in contact microrheological 
measurements under low Reynolds numbers (Re < 1) can be accurately estimated by 𝑏(0) (274). 
 
5.1.3. Oscillation on cell 
The model essentially relies on Hertzian contact mechanics assuming pyramidal indenter 
geometry 
𝐹 =
3𝐸tan(𝜃)
4(1−𝜐2)
𝛿2                                                                                                                           (5.8) 
Where 𝐸 and 𝜐 are the Young’s modulus and the Poisson’s ration of a cell, respectively. 𝜐 is 
assumed to be 0.5 for a RBC. According to Alcaraz et al (161, 274) the complex modulus is given 
by 
𝐺∗(𝜔) = 𝐺′(𝜔) + 𝑖𝐺″(𝜔) =
1−𝜐
3𝛿0tan(𝜃)
𝐹(𝜔)
𝛿(𝜔)
                                                                                               (5.9) 
After correction for the hydrodynamic drag acting on the oscillating cantilever, the expression for 
the complex shear modulus becomes 
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𝐺∗(𝜔) = 𝐺′(𝜔) + 𝑖𝐺″(𝜔) =
1−𝜐
3𝛿0tan(𝜃)
(
𝐹(𝜔)
𝛿(𝜔)
− 𝑖𝜔𝑏(ℎ0))                                                                         (5.10) 
The ration between 𝐹(𝜔) and 𝛿(𝜔) can be calculated from the measured amplitudes 𝐴𝐹(𝜔) and 
𝐴𝛿(𝜔) and phases 𝜑𝐹(𝜔) and 𝜑𝛿(𝜔) with the correction of the system lag 
𝐹(𝜔)
𝛿(𝜔)
=
𝐴𝐹(𝜔)
𝐴𝛿(𝜔)
𝑒𝑖[𝜑𝐹(𝜔)−𝜑𝛿(𝜔)−𝜑𝑙𝑎𝑔]                                                                                                 (5.11) 
 
We applied sinusoidal oscillation loadings to WT-, SCT-, and SS-RBCs. The results showed that 
the storage modulus (elastic modulus) 𝐺′ was insensitive to frequencies 10-100 Hz, but increased 
rapidly at frequencies 100-200 Hz; the loss modulus (frictional modulus) 𝐺″  increased 
substantially with the increasing frequency at 5-200 Hz, see Figure 5.6, 5.7, and 5.8. In addition, 
the storage modulus was larger than the loss modulus for WT- and SCT-RBCs at frequencies 5-
200 Hz, for SS-RBCs at frequencies 5-80 Hz. Distinctively, for SS-RBCs, 𝐺″ crossovered 𝐺′ at 
the frequency of ~80 Hz; above 80 Hz the loss modulus was larger than the storage modulus. 
The domination shift from 𝐺′ to 𝐺″  suggest that SS-RBCs show a more solid-like behavior at low 
frequencies; but behave more like a viscous liquid when exposed to high frequency loadings. 
While WT-RBCs and SCT-RBCs exhibited a predominantly elastic behavior at the whole 
frequency range tested (5-200 Hz). 
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Figure 5.6. WT-RBC G’ & G’’ as a function of the oscillation frequency. Results are 
shown as mean ± SD, including a total of 6 cells. 
 
 
Figure 5.7. SCT-RBC G’ & G’’ as a function of the oscillation frequency. Results are 
shown as mean ± SD, including a total of 6 cells. 
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Figure 5.8. SS-RBC G’ & G’’ as a function of the oscillation frequency. Results are 
shown as mean ± SD, including a total of 6 cells. 
 
5.2. RBC adhesion comparison between normoxic and hypoxic conditions 
In SCD, RBCs expose to low oxygen condition could be a critical point triggering the detrimental 
changes in the cell deformability and adhesion properties. Better understanding of the RBC 
mechanical and adhesive properties under hypoxic conditions is important in order to reverse the 
harmful change or at least reduce the damage. We applied a non-toxic oxygen scavenger agent, 
sodium sulfite, to normal RBCs and measured the cell stiffness and the single cell adhesion to 
αvβ3 integrin. 
A normal blood sample was obtained from freshly drawn, heparin-anticoagulated venous blood 
collected by Research Blood Components, LLC. Whole blood was centrifuged at 500 × g for 5 
min at 4˚C to separate the RBCs. The plasma and buffy coat were extracted and discarded. Then, 
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the remaining RBCs were washed three times with Alsever’s solution and stored at 4˚C for up to 
7 days. 
 
5.2.1. Stiffness measurement under normoxic and hypoxic conditions 
RBCs were seeded in a glass-bottom petri dish (Ted Pella, Redding, CA) that was pretreated with 
1 mg/mL poly-L-lysine solution (Sigma-Aldrich) for 15 min at room temperature. Under these 
conditions, RBCs adhered slightly to the substrate while they maintained their biconcave shape. 
The hypoxic condition was obtained by adding freshly prepared sodium sulfite solution (in PBS, 
1M) to the petri dish. 
The stiffness measurements were carried out in contact mode AFM using silicon nitride 
cantilevers with a nominal spring constant of 0.03 N/m (Bruker Nano, Camarillo, CA). The tip 
height was between 2.5 and 8 mm and the nominal tip radius was 20 nm. Exact values for the 
cantilever spring constants were obtained via a thermal noise based method implemented by the 
manufacturer and were used in all calculations. Measurements were performed in PBS (normoxic) 
or 1M sodium sulfite solution in PBS (hypoxic) at 25°C. The force curves were generated at a 
loading rate of 24,000 pN/s, and for each state, normoxic and hypoxic, 250 measurements were 
collected from a total of 5 cells. 
The results showed that deoxygenated RBCs were significantly softer than oxygenated RBCs 
(Figure 5.9). Young’s modulus values (mean ± SEM) of oxygenated and deoxygenated RBCs 
were 5.68 ± 0.28 kPa, 2.038 ± 0.071 kPa (p<0.0001), respectively. Significance was determined 
using the nonparametric Mann-Whitney test. The results were considered significant if p<0.05. 
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Figure 5.9. Box-and-whisker plot showing Young’s modulus of WT-RBCs under 
normoxic and hypoxic conditions. Data are shown as the median with minimum and 
maximum whiskers, and the mean is denoted as a dot. Significance between conditions is 
denoted as * such that p < 0.0001. The n on the x-axis indicates the total number of mature 
WT-RBCs analyzed in each group, obtained from the same human subject. 
 
5.2.2. Single cell adhesion measurement under normoxic and hypoxic conditions 
Glass petri dishes (Ted Pella, Redding, CA) were divided using a hydrophobic PAP pen (Sigma 
Aldrich, St. Louis, MO) to separate RBCs from the αvβ3 surface (Figure 5.10). Half of the glass 
surface was silanized with 2% v/v APTES in acetone for 10min, rinsed with deionized (DI) water, 
treated with 0.5% v/v glutaraldehyde (solution in DI water) for 30 min, rinsed, incubated in 100 
μg/mL αvβ3 (solution in PBS) for 30min, rinsed, and incubated in 100 μg/mL BSA for 1 min.  
Tipless silicon nitride AFM cantilevers (NanoWorld, Neuchâtel, Switzerland) were soaked in 
acetone for 5min, UV irradiated for 15 min, incubated overnight in 0.5 mg/mL biotin-BSA at 37 ˚C, 
rinsed with PBS and treated with 1% glutaraldehyde for 30s, rinsed, incubated in 0.5mg/mL 
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streptavidin for 10 min, rinsed, and incubated in 0.5 mg/mL biotinylated Con A for 10 min at 25 
˚C. 
Cells were allowed to bind weakly to the non-functionalized region of the glass substrate via 10min 
incubation at 37°C followed by rinsing with PBS solution, thus allowing for cantilever engagement 
with a chosen RBC. Single cells were captured by positioning the Con A functionalized cantilever 
above the cell center (Figure 5.10) and gently lowering onto the cell for ~30s. The cell was then 
lifted from the surface and allowed to establish firm adhesion to the cantilever before relocation 
to the αvβ3-functionalized region of the dish.  
 
Figure 5.10. Schematic of a SCFS experiment between RBCs and the αvβ3-functionalized 
substrate. (A) A tipless Con A-functionalized AFM cantilever capturing a RBC. (B) Relocating 
the attached RBC to the αvβ3-functionalized substrate. (C) A real RBC attached to a tipless 
cantilever. 
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Each SCFS measuring session involved testing a single RBC attached to a previously calibrated 
cantilever for 110 approach/retraction cycles on an αvβ3-functionalized glass substrate. 
Measurements were performed in PBS (normoxic) or 1M sodium sulfite solution in PBS (hypoxic) 
at 25°C. For each state, normoxic and hypoxic, 550 measurements were collected from a total of 
5 cells. 
The results showed that deoxygenated RBCs were significantly more adhesive to the αvβ3-
functionalized substrate than oxygenated RBCs did (Figure 5.11). Detachment forces (mean ± 
SEM) for oxygenated and deoxygenated RBCs were 55.06 ± 0.98 pN, 66.28 ± 1.43 pN (p<0.0001). 
Significance was determined using the nonparametric Mann-Whitney test. The results were 
considered significant if p<0.05. 
 
Figure 5.11. Box-and-whisker plot showing the detachment forces obtained for WT-
RBCs retracting from the αvβ3 substrate under normoxic and hypoxic conditions. Data 
are shown as the median with minimum and maximum whiskers, and the mean is denoted as 
a dot. Significance between conditions is denoted as * such that p < 0.0001. The n on the x-
axis indicates the total number of mature WT-RBCs analyzed in each group, obtained from 
the same human subject. 
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Chapter 6. Epilogue 
Sickle cell disease (SCD) is one of the first genetic diseases ever diagnosed. It is a really painful 
and debilitating chronical disease that can cause shortness of breath, fatigue, delayed growth and 
development in children, yellowing of the eyes and skin, and more serious complications, such 
as pulmonary hypertension and multiple organ damages including brain damage from stroke. In 
SCD, a single point mutation occurs in the β-globin gene and lead to production of abnormal 
hemoglobin HbS which in deoxygenated conditions polymerizes to form stiff filaments. This is 
severely detrimental to the RBC biophysical functions. It not only causes distortion to the shape 
of the RBC from biconcave to "sickled", but also makes the RBC stiffer, more viscous, and show 
higher adhesion than normal (wild-type) WT-RBCs to other RBCs, platelets, leukocytes, and to 
the endothelium. Abnormal SS-RBC adhesion leads to delayed microvascular passage of 
deoxygenated RBCs inducing sickling and entrapment of RBCs triggering vaso-occlusive 
episodes (VOEs) which is the pathophysiologic hallmark of SCD. Anti-adhesive agents have 
shown positive impacts in pre-clinical research and clinical trials and are potential candidates for 
alleviating pain and managing SCD crisis onset. 
Work from others and us (74, 171, 172) has demonstrated that increased SS-RBC adhesion is 
due to higher density of functional adhesion receptors on the RBC membrane. RBC receptor 
activation depends upon intracellular signaling pathways (5) that can be activated by extracellular 
stimuli. One such pathway is cAMP-PKA which can be activated by epinephrine, a catecholamine, 
which binds to G protein-coupled receptor and activates the downstream signaling (74, 172, 173). 
It has been shown that the cAMP-PKA pathway directly regulates the activation of the basal cell 
adhesion molecule/Lutheran (BCAM/Lu) on the RBC surface (172, 174). In addition, studies using 
a variety of adhesion assays including micropipetting and perfusion chambers revealed that SS-
RBCs adhere to endothelial cells (170, 175), inducing endothelial injury and inflammation likely 
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contributing to vaso-occlusive events (65, 170, 176-178). Zennadi et al. (66) further showed that 
intercellular adhesion molecule-4 (ICAM-4) was the primary receptor mediating the adhesion of 
SS-RBCs to endothelial cells and that the ligand for the ICAM-4 receptor was the endothelial αvβ3 
integrin (66, 179, 180). They also identified that epinephrine can stimulate the activation of ICAM-
4 at least partially via the cAMP-PKA dependent signaling pathway. Here, RBC adhesion was 
studied in detail in terms of ICAM-4 activation at single molecule level. We investigated the effects 
of the cAMP-PKA dependent pathway modulation on (i) the binding between ICAM-4 and αvβ3 
and (ii) the expression of active ICAM-4 receptors on the membrane of both WT-RBCs and SS-
RBCs. We also investigated whether AKAPs play a role in ICAM-4 activation. We implemented 
single-molecule force spectroscopy (SMFS) by using an atomic force microscope (AFM) which 
allows for the detection of single functional receptors on cells and at the same time for the 
measurement of the unbinding force between a receptor and the corresponding ligand (172, 192-
198). It also allows detection of variations in the collective frequency (CF) of active ICAM-4 
receptors on the RBC membrane. We used several biochemical reagents that affect the cAMP-
PKA pathway and investigated if the AKAP-PKA complex regulates ICAM-4 activation. In addition, 
we used confocal microscopy to corroborate our AFM results. The findings suggest that activation 
of ICAM-4 adhesion receptors is regulated by the cAMP-PKA signaling pathway and more 
importantly can be mediated via AKAPs.  
Previous research has shown that the adrenergic system and the renin-angiotensin system are 
interrelated, moreover, in human embryonic kidney (HEK) cells, mouse cardiomyocytes, and 
COS-7 cell lines there is a direct interaction and cross-regulation between β-Adrenergic receptor 
(β-AR) and angiotensin II type 1 receptor (AT1R). It was found that a single receptor antagonist 
blocks downstream signaling of both β-AR and AT1R. We made a hypothesis that this cross-talk 
is active in RBCs. Specifically, valsartan, an AT1R blocker, may also have a profound effect on 
attenuating ICAM-4 activation through receptor cross-talk. We employed SMFS to detect the 
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ICAM-4 expression on WT-, SCT-, and SCD-RBCs and found that pretreatment of RBCs with 
valsartan significantly hindered the activation of ICAM-4 receptors induced by epinephrine. The 
findings of this work suggest that administration of valsartan offers a possible way to mitigate 
vaso-occlusive episodes in SCD. In addition, patients with SCD are often prescribed renin–
angiotensin–aldosterone system (RAAS) blockers for management of sickle cell-related 
nephropathy. Thus, valsartan administration may be a multi-beneficial remedy. 
Clinical disparities were observed between African-American and white females in terms of 
adverse events during chemotherapy, particularly among breast cancer patients, and overall 
cancer survival. African-American women have more than 10% lower breast cancer survival than 
white females, and this difference persisted over time. We studied blood samples from patients 
with sickle cell trait (SCT), which is estimated to occur in 8-10% of African-Americans, in cancer 
outcomes. We found that when chemotherapeutic agents interact with the RBC, they influence 
ICAM-4 activation differently in white women with wild type hemoglobin than in African-American 
women with wild type hemoglobin, and African-American women with SCT. This suggests race 
and SCT carrying status may need to be deliberately considered in order to improve patient 
outcomes during cancer chemotherapeutic treatment. 
Further approaches to better understand RBC biophysics were expected to provide 
comprehensive characteristics in terms of RBC rheology and adhesion. AFM can generate and 
apply time-dependent loadings to RBC membrane with a precise control of the loading rate. The 
complex ratio between the applied stress and the resulting strain, defined as complex modulus of 
the material, can be obtained through analysis in the frequency domain. The real and imaginary 
parts describe the elastic and viscous properties respectively, namely the viscoelasticity of a RBC. 
We found that the storage modulus (elastic modulus) 𝐺′ was insensitive to frequencies 10-100 
Hz, but increased rapidly at frequencies 100-200 Hz. The loss modulus (frictional modulus) 𝐺″ 
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increased appreciably with the increasing frequency at 5-200 Hz. In addition, for WT-RBCs and 
SCT-RBCs, the whole frequency domain 5-200 Hz was dominated by 𝐺′  suggesting cells 
exhibited a predominantly elastic behavior. In contrast, there was a cross point between 𝐺′ and 
𝐺″  for SS-RBCs at the frequency of ~80 Hz, below 80 Hz 𝐺′ >  𝐺″ , above 80 Hz 𝐺″ >  𝐺′ , 
suggesting that SS-RBCs show a more solid-like behavior at low frequencies; but behave more 
like a viscous liquid when exposed to high frequency loadings. To better understand the molecular 
mechanisms underlying cell microrheology in health and disease, more comprehensive cell 
structures need to be characterized, including the plasma membrane, the cytoskeleton, and the 
cytosol beneath the deformed cell surface. 
In SCD, RBC deoxygenation most likely would cause changes in the cell motility and adherence, 
leading to painful vaso-occlusive crisis and sometimes severe complications. In order to reverse 
the detrimental changes, better understanding of the mechanical and adhesion properties of the 
RBC in hypoxic conditions is intensively needed. We applied a non-toxic oxygen scavenger agent, 
sodium sulfite, to WT-RBCs and measured the cell stiffness and the single cell adhesion using 
SMFS and SCFS respectively. We found that deoxygenated WT-RBCs were significantly softer 
and more adhesive to αvβ3 than oxygenated WT-RBCs did. The same measurement could be 
extended to SS-RBCs. Better understanding the mechanical and adhesion properties of the SS-
RBCs in hypoxia conditions may be helpful for improving SCD crisis management and impacting 
patient outcomes. More accurate oxygen scavenging and real-time oxygen level measurement 
along with the SMFS and SCFS techniques could further enhance the accuracy of the 
measurement. Oxygen sensing technique, such as fluorescence quenching, may be a good 
choice since it works in a non-destructive manner. 
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